[
  {
    "id": "20251017-011657-22e845ad",
    "createdAt": "2025-10-17T01:16:57.045Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:16:53 PM"
    },
    "articles": [
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      }
    ],
    "markdown": "# 25D-NBOMe · #653\n\n+{\n+  \"title\": \"25D-NBOMe\",\n+  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"drug_info\": {\n+    \"drug_name\": \"25D-NBOMe\",\n+    \"chemical_name\": \"2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine\",\n+    \"alternative_name\": \"2C-D-NBOMe; NBOMe-2C-D; Divination; N-Bomb\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (partial); 5-HT2B receptor agonist; 5-HT2C receptor agonist; adrenergic alpha-1 receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"300 ug\",\n+            \"light\": \"300-800 ug\",\n+            \"common\": \"800-1000 ug\",\n+            \"strong\": \"1000-1200 ug\",\n+            \"heavy\": \"1200+ ug\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"200 ug\",\n+            \"light\": \"200-600 ug\",\n+            \"common\": \"600-800 ug\",\n+            \"strong\": \"800-1000 ug\",\n+            \"heavy\": \"1000+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"6+ hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"3-5 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"25D-NBOMe has not been formally studied for addiction potential but appears to have a self-regulating quality with immediate tolerance buildup. Rapid tolerance develops after use, lasting approximately 2-3 weeks. Animal studies have shown reinforcing effects including conditioned place preference and self-administration behavior, suggesting some potential for psychological reinforcement.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MAOIs (hypertensive crisis risk, unpredictable potentiation)\",\n+        \"Amphetamines (severe cardiovascular stress, tachycardia, hypertension, potential heart failure)\",\n+        \"Cocaine (severe vasoconstriction, tachycardia, hypertension, potential heart failure)\"\n+      ],\n+      \"unsafe\": [\n+        \"2C-T-X compounds (unpredictable interactions)\",\n+        \"5-MeO-xxt compounds (unpredictable interactions)\",\n+        \"aMT (unpredictable cardiovascular effects)\",\n+        \"DOx compounds (prolonged stimulation, cardiovascular strain)\",\n+        \"DXM (unpredictable effects)\",\n+        \"MDMA (cardiovascular strain, hyperthermia risk)\",\n+        \"MXE (potentiation of NBOMe effects)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (significantly increases anxiety, paranoia, and unpredictable psychological effects)\",\n+        \"Caffeine (increases uncomfortable stimulation and anxiety)\",\n+        \"SSRIs (may blunt or prolong effects)\"\n+      ]\n+    },\n+    \"notes\": \"25D-NBOMe is a highly potent research chemical with an extremely narrow margin between active and potentially lethal doses. The compound is not orally active and must be administered sublingually or via other mucosal routes. Never insufflate NBOMe compounds as this route has been associated with numerous fatalities. Blotter paper doses are notoriously inconsistent due to hotspots of concentrated material. Use only with an analytical balance for weighing, never eyeball doses. Those with personal or family history of psychotic disorders, cardiovascular conditions, or seizure disorders should avoid this substance entirely. The compound produces dose-dependent vasoconstriction and cardiovascular strain. Set and setting are critical; always have a sober trip sitter present. Many deaths have occurred from individuals believing they consumed LSD when they actually ingested an NBOMe compound.\",\n+    \"subjective_effects\": [\n+      \"Visual Acuity Enhancement\",\n+      \"Color Enhancement\",\n+      \"Visual Geometry\",\n+      \"Tracers and After Images\",\n+      \"Physical Euphoria\",\n+      \"Stimulation\",\n+      \"Tactile Hallucination\",\n+      \"Time Distortion\",\n+      \"Mouth and Tongue Numbness\",\n+      \"Metallic Chemical Taste\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Thought Acceleration\",\n+      \"Music Appreciation Enhancement\",\n+      \"Emotional Amplification\",\n+      \"Nausea\",\n+      \"Vasoconstriction\",\n+      \"Increased Heart Rate\",\n+      \"Increased Blood Pressure\",\n+      \"Temperature Regulation Suppression\",\n+      \"Muscle Tension and Cramps\",\n+      \"Headaches\",\n+      \"Anxiety and Paranoia\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops immediately after use\",\n+      \"half_tolerance\": \"Approximately 1 week\",\n+      \"zero_tolerance\": \"2-3 weeks\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\",\n+        \"Other NBOMe compounds\",\n+        \"2C-x series\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (parent compound rapidly cleared from blood)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Alcohol and Drug Foundation: NBOMes\",\n+        \"reference\": \"https://adf.org.au/drug-facts/nbomes/\"\n+      },\n+      {\n+        \"name\": \"Erowid 25D-NBOMe Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_25DNBOMe.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid NBOMe Series Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nbome/\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Neuroscience: NBOMes - Highly Potent and Toxic Alternatives of LSD\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fnins.2020.00078/full\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 25D-NBOMe\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=342\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 25D-NBOMe\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25D-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 25D-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25D-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Yoon et al. (2019): Cardiac Effects of 25D-NBOMe and 25C-NBOMe\",\n+        \"reference\": \"https://doi.org/10.1016/j.toxlet.2019.01.004\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"research-chemical\",\n+      \"nbome-series\",\n+      \"phenethylamine\"\n+    ]\n+  },\n+  \"id\": 653\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-011004-caa3a24b",
    "createdAt": "2025-10-17T01:10:04.318Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:10:02 PM"
    },
    "articles": [
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      }
    ],
    "markdown": "# 25C-NBOH · #652\n\n+{\n+  \"title\": \"25C-NBOH\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"25C-NBOH\",\n+    \"chemical_name\": \"2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine\",\n+    \"alternative_name\": \"2C-C-NBOH; NBOH-2C-C; N-bomb; NBOH\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent, pEC50 9.43); 5-HT2C receptor agonist (pKi 7.8)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"100 ug\",\n+            \"light\": \"250-500 ug\",\n+            \"common\": \"500-750 ug\",\n+            \"strong\": \"750-1000 ug\",\n+            \"heavy\": \"1000+ ug (potentially fatal)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"stages\": {\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"15-45 minutes\",\n+            \"peak\": \"90-180 minutes (come up 30-90 minutes)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"3-6 days (afterglow may persist)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"25C-NBOH is not considered habit-forming and the desire to use it typically decreases with repeated use. The substance is generally self-regulating, though research on its addiction potential is extremely limited.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"MAOIs (potentially dangerous interaction)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictably strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"25C-NBOH is a novel research chemical with extremely limited human use history and assumed similar toxicity to 25C-NBOMe, which has been linked to multiple deaths. This substance must NEVER be insufflated (snorted) due to high risk of fatal overdose. Compounds of the NBOH family are NOT orally active and must be administered sublingually, holding in the mouth for 15-25 minutes. Use an accurate microgram scale for all dosing. The substance exhibits dose-independent intensity and unpredictable effects even at seemingly identical doses. Start with threshold doses and avoid combinations. Heavy doses may be fatal. Individuals with personal or family history of psychotic disorders should avoid use. This substance is controlled in many jurisdictions.\",\n+    \"subjective_effects\": [\n+      \"Intense Visual Patterning And Geometry\",\n+      \"Strong Physical Stimulation\",\n+      \"Perception Of Bodily Lightness\",\n+      \"Color Enhancement\",\n+      \"Time Distortion\",\n+      \"Spontaneous Euphoric Tingling Sensations\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Mouth And Tongue Numbing\",\n+      \"Nausea (Typically During Come-Up)\",\n+      \"Anxiety And Paranoia (More Common Than Classical Psychedelics)\",\n+      \"Mild Cognitive Effects (Notably Light Headspace)\",\n+      \"Increased Sociability And Empathy (Inconsistent)\",\n+      \"Enhanced Music Appreciation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"Approximately 1 week\",\n+      \"zero_tolerance\": \"2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x series, NBOMe series)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 25C-NBOH Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-25c-nboh-thread.621629/\"\n+      },\n+      {\n+        \"name\": \"Erowid 25C-NBOH Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_25CNBOH.shtml\"\n+      },\n+      {\n+        \"name\": \"Hansen, M. (2012). Design and Synthesis of Selective Serotonin Receptor Agonists for PET Imaging\",\n+        \"reference\": \"https://www.researchgate.net/publication/266388124\"\n+      },\n+      {\n+        \"name\": \"Hansen et al. (2014). Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists\",\n+        \"reference\": \"https://doi.org/10.1021/cn400216u\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 25C-NBOH\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=1252\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 25C-NBOH\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25C-NBOH\"\n+      },\n+      {\n+        \"name\": \"Silva et al. (2011). Theoretical Studies on the Interaction of Partial Agonists with the 5-HT2A Receptor\",\n+        \"reference\": \"https://doi.org/10.1007/s10822-010-9400-2\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"research-chemical\",\n+      \"nboh-series\"\n+    ]\n+  },\n+  \"id\": 652\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-010656-f750f60d",
    "createdAt": "2025-10-17T01:06:56.440Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:06:53 PM"
    },
    "articles": [
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      }
    ],
    "markdown": "# DOI · #651\n\n+{\n+  \"title\": \"DOI\",\n+  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"drug_info\": {\n+    \"drug_name\": \"DOI\",\n+    \"chemical_name\": \"2,5-Dimethoxy-4-iodoamphetamine\",\n+    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n+    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n+    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2B receptor agonist; 5-HT2C receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"16-24 hours\",\n+            \"onset\": \"1-2 hours\",\n+            \"peak\": \"3-6 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"6-12 hours\",\n+            \"after_effects\": \"24-48 hours (residual stimulation)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"DOI is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. There is no evidence of physical dependence or compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants such as amphetamine, cocaine, or methylphenidate (increased risk of anxiety, paranoia, thought loops, and psychosis)\",\n+        \"MAOIs (potential for unpredictable interactions)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significant increase in anxiety, paranoia, and psychosis risk)\",\n+        \"5-MeO tryptamines (unpredictable interactions with increased physical side effects)\",\n+        \"MDMA (combined stimulating effects can be uncomfortable and anxiogenic during comedown)\",\n+        \"Caffeine (may cause anxiety and physical discomfort)\",\n+        \"Amphetamines (uncomfortable body load and thought loops)\",\n+        \"Cocaine (uncomfortable body load and thought loops)\",\n+        \"Ketamine (potentiation; go slowly)\",\n+        \"Alcohol (reduced sedative effects lead to excessive drinking)\"\n+      ]\n+    },\n+    \"notes\": \"DOI is an extremely potent and long-lasting psychedelic with a very sensitive dose-response curve. It is sometimes sold falsely as LSD, which can be dangerous due to differing safety profiles and dosage ranges. Use a precise milligram scale for accurate dosing. The exceptionally long duration of 16-24 hours with residual stimulation lasting up to 48 hours requires adequate time preparation. Individuals with personal or family history of psychotic disorders should avoid use. Start with the lowest possible dose due to high individual variability in response.\",\n+    \"subjective_effects\": [\n+      \"Extreme Stimulation\",\n+      \"Visual Patterning And Geometry\",\n+      \"Colour Enhancement\",\n+      \"Energetic Body High\",\n+      \"Thought Acceleration\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Internal And External Hallucinations\",\n+      \"Time Distortion\",\n+      \"Emotional Amplification\",\n+      \"Enhanced Music Appreciation\",\n+      \"Nausea\",\n+      \"Muscle Tension And Vasoconstriction\",\n+      \"Increased Body Temperature\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, DOx compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"Unknown; estimated duration of primary effects 16-24 hours with residual effects up to 48 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Coutts & Malicky 1973 - Synthesis of DOI Analogs\",\n+        \"reference\": \"https://doi.org/10.1139/v73-210\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki DOI Profile\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DOI\"\n+      },\n+      {\n+        \"name\": \"TripSit DOI Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/DOI\"\n+      },\n+      {\n+        \"name\": \"Erowid DOI Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/doi/doi.shtml\"\n+      },\n+      {\n+        \"name\": \"PiHKAL Entry #67 - DOI (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=67\"\n+      },\n+      {\n+        \"name\": \"Shulgin & Shulgin - PiHKAL: A Chemical Love Story\",\n+        \"reference\": \"Transform Press, 1991\"\n+      },\n+      {\n+        \"name\": \"Bluelight DOI Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-doi-thread.216778/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"stimulant\",\n+      \"substituted-amphetamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 651\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-005710-3997dc11",
    "createdAt": "2025-10-17T00:57:10.029Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:57:08 PM"
    },
    "articles": [
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      }
    ],
    "markdown": "# 2,5-DMA · #650\n\n+{\n+  \"title\": \"2,5-DMA\",\n+  \"index-category\": \"stimulant; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"2,5-DMA\",\n+    \"chemical_name\": \"1-(2,5-Dimethoxyphenyl)propan-2-amine\",\n+    \"alternative_name\": \"2,5-Dimethoxyamphetamine; DMA; DOH\",\n+    \"chemical_class\": \"Amphetamines; Phenethylamines\",\n+    \"psychoactive_class\": \"Stimulant; Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (low potency); does not bind to monoamine transporters\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10-40 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"2,5-DMA is not considered habit-forming and likely has low psychological dependence potential. However, its stimulating properties may present some risk of compulsive use similar to other stimulants. No formal studies have been conducted on addiction potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (unpredictable synergy, increased risk of anxiety and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (increased anxiety, paranoia, and cardiovascular risk)\",\n+        \"Other psychedelics (may intensify effects unpredictably)\"\n+      ]\n+    },\n+    \"notes\": \"2,5-DMA is a research chemical and the simplest member of the DOx family, primarily known as a precursor in synthesizing other psychedelic amphetamines rather than for its own psychoactive effects. Unlike typical psychedelics, it produces primarily stimulant and physical effects with minimal to no sensory or perceptual changes. Very little data exists about its pharmacology, metabolism, and toxicity. Use accurate weighing equipment and start with lower doses due to individual variability. Those with personal or family history of mental health disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Physical Stimulation\",\n+      \"Increased Heart Rate\",\n+      \"Increased Blood Pressure\",\n+      \"Pupil Dilation\",\n+      \"Muscle Tension\",\n+      \"Tremors\",\n+      \"Body Load\",\n+      \"Enhanced Interest In Surroundings\",\n+      \"Cardiovascular Stimulation\",\n+      \"Temperature Regulation Suppression\",\n+      \"Increased Perspiration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"7-10 days\",\n+      \"cross_tolerances\": [\n+        \"Psychedelics (unlikely but possible)\",\n+        \"Stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Baltzly & Buck, 1940 - Original Synthesis\",\n+        \"reference\": \"https://doi.org/10.1021/ja01858a046\"\n+      },\n+      {\n+        \"name\": \"Erowid PiHKAL #54: 2,5-DMA\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal054.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design PiHKAL Info: 2,5-DMA\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=54\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 2,5-DMA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2,5-DMA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 2,5-Dimethoxyamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2,5-Dimethoxyamphetamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"amphetamine\",\n+      \"phenethylamine\",\n+      \"dox-family\",\n+      \"research-chemical\",\n+      \"stimulant\"\n+    ]\n+  },\n+  \"id\": 650\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-005331-24a27364",
    "createdAt": "2025-10-17T00:53:31.846Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:53:29 PM"
    },
    "articles": [
      {
        "id": 649,
        "title": "2C-T",
        "slug": "2c-t"
      }
    ],
    "markdown": "# 2C-T · #649\n\n+{\n+  \"title\": \"2C-T\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"2C-T\",\n+    \"chemical_name\": \"2,5-Dimethoxy-4-methylthiophenethylamine\",\n+    \"alternative_name\": \"Tesseract\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potential MAOI properties\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"40-60 mg\",\n+            \"common\": \"60-100 mg\",\n+            \"strong\": \"100-120 mg\",\n+            \"heavy\": \"125+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"30-115 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-2 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"2C-T is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating with no significant dependence or abuse potential reported.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (potential serotonin syndrome or neurotransmitter overload)\",\n+        \"Stimulants (increased neurotransmitter release)\",\n+        \"5-MeO-MiPT (serotonergic overload)\",\n+        \"2C-T-7 (serotonergic overload)\",\n+        \"AMT (MAOI properties)\",\n+        \"Cocaine (cardiovascular stress)\",\n+        \"Methamphetamine (neurotoxicity risk)\",\n+        \"MDMA (serotonin syndrome risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"2-AI (serotonergic interaction)\",\n+        \"A-PVP (cardiovascular stress)\",\n+        \"Amphetamine (increased strain)\",\n+        \"Mephedrone (combined stimulation)\"\n+      ]\n+    },\n+    \"notes\": \"2C-T is a lesser-known research chemical with very limited human use history and minimal scientific data on its pharmacology, metabolism, and toxicity. It is structurally similar to 2C-T-2 and 2C-T-7 and may possess MAOI properties, making it potentially more dangerous when combined with other serotonergic substances. The substance is illegal in many jurisdictions including the United States (Schedule I), United Kingdom (Class A), and Canada (Schedule III). Use accurate milligram scales for dosing, practice harm reduction, and consider having a sober trip sitter present. Individuals with personal or family histories of mental health conditions should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Spontaneous Bodily Sensations\",\n+      \"Tactile Enhancement\",\n+      \"Bodily Control Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Analysis Enhancement\",\n+      \"Time Distortion\",\n+      \"Increased Music Appreciation\",\n+      \"Colour Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Drifting and Morphing\",\n+      \"Nausea\",\n+      \"Vasoconstriction\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Nichols & Shulgin (1976) - Sulfur Analogs of Psychotomimetic Amines\",\n+        \"reference\": \"https://doi.org/10.1002/jps.2600651040\"\n+      },\n+      {\n+        \"name\": \"PiHKAL Entry #39: 2C-T\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=39\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 2C-T\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2C-T\"\n+      },\n+      {\n+        \"name\": \"Erowid 2C-T-2 Basics\",\n+        \"reference\": \"https://erowid.org/chemicals/2ct2/2ct2_basics.shtml\"\n+      },\n+      {\n+        \"name\": \"Gallardo-Godoy et al. (2005) - Sulfur-Substituted MAO-A Inhibitors\",\n+        \"reference\": \"https://doi.org/10.1021/jm0493109\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"research-chemical\",\n+      \"2c-x\"\n+    ]\n+  },\n+  \"id\": 649\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-004937-559d1cc3",
    "createdAt": "2025-10-17T00:49:37.836Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:49:35 PM"
    },
    "articles": [
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      }
    ],
    "markdown": "# Proscaline · #648\n\n+{\n+  \"title\": \"Proscaline\",\n+  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Proscaline\",\n+    \"chemical_name\": \"4-Propyloxy-3,5-dimethoxyphenethylamine\",\n+    \"alternative_name\": \"P; 4-Propoxy-3,5-DMPEA; 3,5-Dimethoxy-4-n-propoxyphenethylamine\",\n+    \"chemical_class\": \"Phenethylamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"3-5 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Proscaline is not habit-forming and demonstrates a self-regulating usage pattern. The desire to use it typically decreases with repeated consumption. There is no evidence of physical dependence or compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of seizures and psychosis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MAOIs (potentially hazardous serotonergic interaction)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (increased cardiovascular strain)\",\n+        \"Cannabis (may intensify and prolong effects unpredictably)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Alcohol (reduces therapeutic potential and increases risk of dehydration)\"\n+      ]\n+    },\n+    \"notes\": \"Proscaline is a lesser-known mescaline analog approximately five times more potent than mescaline. The substance has minimal research into its pharmacology and toxicity. Use a precise milligram scale for accurate dosing. It is controlled in Germany, Switzerland, and the United Kingdom but remains unscheduled in the United States. Individuals with personal or family history of psychotic disorders should avoid use. Ensure adequate set and setting preparation, as with all psychedelics.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Enhancement\",\n+      \"Color Enhancement\",\n+      \"Time Distortion\",\n+      \"Enhanced Music Appreciation\",\n+      \"Tactile Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Conceptual Thinking\",\n+      \"Increased Body Temperature\",\n+      \"Nausea\",\n+      \"Enhanced Introspection\",\n+      \"Emotional Amplification\",\n+      \"Drifting Visual Effects\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Proscaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Proscaline\"\n+      },\n+      {\n+        \"name\": \"PiHKAL Entry #140: Proscaline (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/140\"\n+      },\n+      {\n+        \"name\": \"Erowid PiHKAL: Proscaline\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal140.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Proscaline Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Proscaline.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Proscaline Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/proscaline-new-experience-shiny-happy-people.522598/\"\n+      },\n+      {\n+        \"name\": \"Nichols and Dyer (1977) - Journal of Medicinal Chemistry\",\n+        \"reference\": \"https://doi.org/10.1021/jm00212a022\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"mescaline-analog\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 648\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-004607-55af38b6",
    "createdAt": "2025-10-17T00:46:07.580Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:46:03 PM"
    },
    "articles": [
      {
        "id": 647,
        "title": "Escaline",
        "slug": "escaline"
      }
    ],
    "markdown": "# Escaline · #647\n\n+{\n+  \"title\": \"Escaline\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Escaline\",\n+    \"chemical_name\": \"3,5-Dimethoxy-4-ethoxyphenethylamine\",\n+    \"alternative_name\": \"E; 4-Ethoxy-3,5-dimethoxyphenethylamine\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (5-8 times greater affinity than mescaline); 5-HT2C receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20-25 mg\",\n+            \"light\": \"30-50 mg\",\n+            \"common\": \"50-100 mg\",\n+            \"strong\": \"100-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"40-120 minutes\",\n+            \"peak\": \"5-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"3-5 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Escaline is not considered habit-forming and the desire to use it typically decreases with use. It is generally self-regulating and lacks compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increases risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of adverse psychological reactions)\"\n+      ]\n+    },\n+    \"notes\": \"Escaline is a research chemical with very limited human use history and no formal toxicology studies. It is controlled as a Schedule I substance in the United States, Germany, Japan, Switzerland, and the UK. Users report more intense negative physical side effects compared to mescaline, including heavier body load and greater stimulation. Accurate weighing with a milligram scale is essential. The compound has a very long onset and extended duration, making sleep difficult without sedatives.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Enhanced Music Appreciation\",\n+      \"Visual Patterning And Drifting\",\n+      \"Color Enhancement\",\n+      \"Thought Acceleration And Connectivity\",\n+      \"Time Distortion\",\n+      \"Bodily Sensations\",\n+      \"Pupil Dilation\",\n+      \"Increased Heart Rate\",\n+      \"Muscle Tension\",\n+      \"Euphoria\",\n+      \"Temperature Dysregulation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Blaazer et al. (2008) - ChemMedChem\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/18666267/\"\n+      },\n+      {\n+        \"name\": \"Erowid Escaline Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Escaline.shtml\"\n+      },\n+      {\n+        \"name\": \"Halberstadt & Geyer (2018) - PMC\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848748/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: Escaline (PiHKAL Entry #72)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/72\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Escaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Escaline\"\n+      },\n+      {\n+        \"name\": \"Shulgin & Shulgin (1991) - PiHKAL Entry #72\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/pk/72\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy Escaline Thread - Bluelight\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-escaline-thread.656624/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"mescaline-analog\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 647\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-003112-5d53dfd6",
    "createdAt": "2025-10-17T00:31:12.900Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:31:10 PM"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-  \"title\": \"Psilocybin mushrooms\",\n+  \"title\": \"Psilocybin Mushrooms\",\n-    \"drug_name\": \"Psilocybin mushrooms\",\n-    \"chemical_name\": \"Psilocybin\",\n-    \"alternative_name\": \"Psilocybe cubensis; Magic mushrooms; Shrooms\",\n+    \"drug_name\": \"Psilocybin Mushrooms\",\n+    \"chemical_name\": \"4-Phosphoryloxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Magic Mushrooms; Shrooms; Mushies; Psychedelic Mushrooms; Boomers; Magic Truffles\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (psilocin acts as prodrug)\",\n-          \"units\": \"g (dried mushrooms)\",\n+          \"units\": \"g\",\n-            \"threshold\": \"0.25 g\",\n-            \"light\": \"0.5 - 1 g\",\n-            \"common\": \"1 - 2.5 g\",\n-            \"strong\": \"2.5 - 4 g\",\n-            \"heavy\": \"4+ g\"\n+            \"threshold\": \"0.1-0.5 g\",\n+            \"light\": \"0.5-1.5 g\",\n+            \"common\": \"1.5-3.5 g\",\n+            \"strong\": \"3.5-5 g\",\n+            \"heavy\": \"5+ g\"\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.1-0.3 g\",\n+            \"light\": \"0.3-1 g\",\n+            \"common\": \"1-2.5 g\",\n+            \"strong\": \"2.5-3.5 g\",\n+            \"heavy\": \"3.5+ g\"\n+          }\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n-            \"total_duration\": \"4 - 6 hours\",\n-            \"onset\": \"20 - 60 minutes\",\n-            \"peak\": \"2 - 3 hours\",\n-            \"offset\": \"1 - 2 hours\",\n-            \"after_effects\": \"Up to 24 hours (residual effects, afterglow)\"\n-          },\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n-          ]\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n-    \"addiction_potential\": \"Psilocybin mushrooms have a very low addiction potential. They are not considered habit-forming and tolerance develops rapidly, discouraging frequent use.\",\n+    \"addiction_potential\": \"Psilocybin mushrooms are not considered physically addictive and have low potential for psychological dependence. Rapid tolerance development discourages frequent use. They are not associated with compulsive drug-seeking behavior or withdrawal symptoms.\",\n-        \"MAOIs (can dangerously potentiate effects)\"\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"MAOIs (risk of hypertensive crisis)\"\n-        \"SSRIs (may blunt effects)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Other psychedelics (unpredictable and overwhelming intensity)\"\n-        \"Other psychedelics (increased risk of overwhelming experience)\"\n+        \"Cannabis (unpredictable and significantly intensified effects; increased anxiety, paranoia, and psychosis risk)\",\n+        \"Amphetamines (increased anxiety and thought loop risk)\",\n+        \"Cocaine (increased anxiety and thought loop risk)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Benzodiazepines (may dampen experience; useful for trip abortion)\",\n+        \"Alcohol (may cause dehydration and nausea; can reduce anxiety in low doses)\",\n+        \"MDMA (unknown toxicity; may increase neurotoxicity)\"\n-    \"notes\": \"Penis Envy is a well-known strain of Psilocybe cubensis, notable for its higher potency compared to most other P. cubensis strains. Users report that 1 gram of Penis Envy can be as potent as 2 grams of a standard cubensis strain. Effects are highly dose-dependent and can include intense visual and cognitive changes. Set and setting are crucial for a safe experience. Potency can vary depending on cultivation and genetics.\",\n+    \"notes\": \"Psilocybin mushrooms vary widely in potency by species, strain, and individual specimen; accurate weighing with a precise scale is essential. Dried mushrooms are approximately 10 times more potent by weight than fresh mushrooms. Exercise extreme caution when foraging wild mushrooms due to the risk of consuming poisonous look-alike species; identification should only be performed by experts. Individuals with personal or family history of psychotic disorders should avoid use. Set and setting strongly influence the experience; ensure a safe, comfortable, familiar environment and consider having a trusted sober trip sitter present, especially for first-time users or higher doses.\",\n-      \"Visual distortions\",\n-      \"Euphoria\",\n-      \"Altered thinking\",\n-      \"Time dilation\",\n-      \"Synesthesia\",\n-      \"Spiritual or mystical experiences\",\n-      \"Emotional lability\",\n-      \"Introspection\",\n-      \"Body high\",\n-      \"Nausea (sometimes)\"\n+      \"Visual Geometry and Patterning\",\n+      \"Enhanced Mood and Euphoria\",\n+      \"Time Distortion\",\n+      \"Emotional Enhancement and Amplification\",\n+      \"Spirituality and Mystical Experiences\",\n+      \"Ego Loss and Dissolution\",\n+      \"Enhanced Introspection\",\n+      \"Conceptual Thinking\",\n+      \"Unity and Interconnectedness\",\n+      \"Nausea (especially during come-up)\",\n+      \"Sedation and Body Heaviness\",\n+      \"Confusion\",\n+      \"Anxiety or Feelings of Impending Doom (typically during onset)\",\n+      \"Synaesthesia\",\n+      \"Tactile Enhancement\",\n+      \"Excessive Yawning\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"2 weeks\",\n+      \"full_tolerance\": \"After 1-2 consecutive days of use\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7-14 days\",\n-        \"Other tryptamine psychedelics (e.g., LSD, DMT)\"\n+        \"All psychedelics (LSD, mescaline, 2C-x, tryptamines)\"\n-    \"half_life\": \"1.5 - 3 hours (psilocybin); effects last longer due to active metabolite psilocin\",\n+    \"half_life\": \"1-3 hours (psilocin active metabolite)\",\n-        \"name\": \"Bluelight - Penis Envy Mushrooms Discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/penis-envy-mushrooms.520747/post-11662949\"\n+        \"name\": \"Erowid Psilocybin Mushroom Dosage\",\n+        \"reference\": \"https://erowid.org/plants/mushrooms/mushrooms_dose.shtml\"\n-        \"name\": \"Bluelight - Getting the Most Out of Mushrooms\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/getting-the-most-out-of-mushrooms.555352/page-2\"\n+        \"name\": \"PsychonautWiki: Psilocybin Mushrooms\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushrooms\"\n-        \"name\": \"Tripsitter Substack: Penis Envy Mushrooms\",\n-        \"reference\": \"https://tripsitter.substack.com/p/penis-envy-mushrooms?r=1da21z\"\n+        \"name\": \"TripSit Mushrooms Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/Mushrooms\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Psilocybin Mushrooms Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-psilocybin-mushrooms-thread.58587/\"\n+      },\n+      {\n+        \"name\": \"Drug Science: Psilocybin\",\n+        \"reference\": \"https://www.drugscience.org.uk/psilocybin\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Psychiatry: Therapeutic use of psilocybin\",\n+        \"reference\": \"https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1040217/full\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Psilocybin Mushroom Lemon Tek\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushroom_lemon_tek\"\n-      \"common\"\n+      \"classic-psychedelic\",\n+      \"tryptamine\",\n+      \"plant-based\"\n-  \"index-category\": \"\"\n+  \"index-category\": \"psychedelic;classic;tryptamine\"\n\n# Psilocin · #645\n\n+{\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+      ]\n+    },\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n+      \"Time Distortion\",\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+      },\n+      {\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"serotonergic\",\n+      \"entheogen\"\n+    ]\n+  },\n+  \"id\": 645\n+}\n\n# Allylescaline · #646\n\n+{\n+  \"title\": \"Allylescaline\",\n+  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Allylescaline\",\n+    \"chemical_name\": \"4-Allyloxy-3,5-dimethoxyphenethylamine\",\n+    \"alternative_name\": \"AL; 4-allyloxy-3,5-dimethoxy-phenethylamine\",\n+    \"chemical_class\": \"Phenethylamines; Scalines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"20-30 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"45-240 minutes\",\n+            \"after_effects\": \"Up to 12 hours (residual effects possible)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Allylescaline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating, with little evidence of compulsive redosing patterns. However, given the limited human usage data, these observations should be considered preliminary.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (increased seizure risk with psychedelics)\",\n+        \"Tramadol (lowers seizure threshold with psychedelics)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"MAOIs (theoretical risk based on phenethylamine structure)\",\n+        \"Stimulants (increased body load and cardiovascular strain)\",\n+        \"Other psychedelics (cross-tolerance and unpredictable intensity)\",\n+        \"Dissociatives (unpredictable combination effects)\"\n+      ]\n+    },\n+    \"notes\": \"Allylescaline is a research chemical with very little history of human usage and no formal toxicology studies. As a structural analog of mescaline with significantly increased potency, accurate weighing with a milligram scale is essential. The substance has a notably slow and variable onset ranging from 45 minutes to 4 hours, which may lead to accidental overdosing if users redose prematurely. Legal status varies by jurisdiction; it is controlled in Germany, Japan, Sweden, Switzerland, and the United Kingdom. Set and setting remain important considerations, and individuals with personal or family histories of mental health conditions should exercise extreme caution.\",\n+    \"subjective_effects\": [\n+      \"Physical Stimulation\",\n+      \"Spontaneous Tactile Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Drifting and Flowing Visuals\",\n+      \"Cognitive Euphoria\",\n+      \"Enhanced Empathy and Sociability\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Allylescaline Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Allylescaline.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design - PiHKAL Entry #2: AL\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=2\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki - Allylescaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Allylescaline\"\n+      },\n+      {\n+        \"name\": \"Shulgin, A.; Shulgin, A. (1991). PiHKAL: A Chemical Love Story, Entry #2\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal002.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight - The Big & Dandy Allylescaline Thread\",\n+        \"reference\": \"https://bluelight.org\"\n+      },\n+      {\n+        \"name\": \"Kolaczynska et al. (2022). Receptor interaction profiles of mescaline derivatives\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8865417/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"research-chemical\",\n+      \"mescaline-analog\"\n+    ]\n+  },\n+  \"id\": 646\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-002601-680627a7",
    "createdAt": "2025-10-17T00:26:01.353Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:25:59 PM"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-  \"title\": \"Psilocybin mushrooms\",\n+  \"title\": \"Psilocybin Mushrooms\",\n-    \"drug_name\": \"Psilocybin mushrooms\",\n-    \"chemical_name\": \"Psilocybin\",\n-    \"alternative_name\": \"Psilocybe cubensis; Magic mushrooms; Shrooms\",\n+    \"drug_name\": \"Psilocybin Mushrooms\",\n+    \"chemical_name\": \"4-Phosphoryloxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Magic Mushrooms; Shrooms; Mushies; Psychedelic Mushrooms; Boomers; Magic Truffles\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (psilocin acts as prodrug)\",\n-          \"units\": \"g (dried mushrooms)\",\n+          \"units\": \"g\",\n-            \"threshold\": \"0.25 g\",\n-            \"light\": \"0.5 - 1 g\",\n-            \"common\": \"1 - 2.5 g\",\n-            \"strong\": \"2.5 - 4 g\",\n-            \"heavy\": \"4+ g\"\n+            \"threshold\": \"0.1-0.5 g\",\n+            \"light\": \"0.5-1.5 g\",\n+            \"common\": \"1.5-3.5 g\",\n+            \"strong\": \"3.5-5 g\",\n+            \"heavy\": \"5+ g\"\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.1-0.3 g\",\n+            \"light\": \"0.3-1 g\",\n+            \"common\": \"1-2.5 g\",\n+            \"strong\": \"2.5-3.5 g\",\n+            \"heavy\": \"3.5+ g\"\n+          }\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n-            \"total_duration\": \"4 - 6 hours\",\n-            \"onset\": \"20 - 60 minutes\",\n-            \"peak\": \"2 - 3 hours\",\n-            \"offset\": \"1 - 2 hours\",\n-            \"after_effects\": \"Up to 24 hours (residual effects, afterglow)\"\n-          },\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n-          ]\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n-    \"addiction_potential\": \"Psilocybin mushrooms have a very low addiction potential. They are not considered habit-forming and tolerance develops rapidly, discouraging frequent use.\",\n+    \"addiction_potential\": \"Psilocybin mushrooms are not considered physically addictive and have low potential for psychological dependence. Rapid tolerance development discourages frequent use. They are not associated with compulsive drug-seeking behavior or withdrawal symptoms.\",\n-        \"MAOIs (can dangerously potentiate effects)\"\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"MAOIs (risk of hypertensive crisis)\"\n-        \"SSRIs (may blunt effects)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Other psychedelics (unpredictable and overwhelming intensity)\"\n-        \"Other psychedelics (increased risk of overwhelming experience)\"\n+        \"Cannabis (unpredictable and significantly intensified effects; increased anxiety, paranoia, and psychosis risk)\",\n+        \"Amphetamines (increased anxiety and thought loop risk)\",\n+        \"Cocaine (increased anxiety and thought loop risk)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Benzodiazepines (may dampen experience; useful for trip abortion)\",\n+        \"Alcohol (may cause dehydration and nausea; can reduce anxiety in low doses)\",\n+        \"MDMA (unknown toxicity; may increase neurotoxicity)\"\n-    \"notes\": \"Penis Envy is a well-known strain of Psilocybe cubensis, notable for its higher potency compared to most other P. cubensis strains. Users report that 1 gram of Penis Envy can be as potent as 2 grams of a standard cubensis strain. Effects are highly dose-dependent and can include intense visual and cognitive changes. Set and setting are crucial for a safe experience. Potency can vary depending on cultivation and genetics.\",\n+    \"notes\": \"Psilocybin mushrooms vary widely in potency by species, strain, and individual specimen; accurate weighing with a precise scale is essential. Dried mushrooms are approximately 10 times more potent by weight than fresh mushrooms. Exercise extreme caution when foraging wild mushrooms due to the risk of consuming poisonous look-alike species; identification should only be performed by experts. Individuals with personal or family history of psychotic disorders should avoid use. Set and setting strongly influence the experience; ensure a safe, comfortable, familiar environment and consider having a trusted sober trip sitter present, especially for first-time users or higher doses.\",\n-      \"Visual distortions\",\n-      \"Euphoria\",\n-      \"Altered thinking\",\n-      \"Time dilation\",\n-      \"Synesthesia\",\n-      \"Spiritual or mystical experiences\",\n-      \"Emotional lability\",\n-      \"Introspection\",\n-      \"Body high\",\n-      \"Nausea (sometimes)\"\n+      \"Visual Geometry and Patterning\",\n+      \"Enhanced Mood and Euphoria\",\n+      \"Time Distortion\",\n+      \"Emotional Enhancement and Amplification\",\n+      \"Spirituality and Mystical Experiences\",\n+      \"Ego Loss and Dissolution\",\n+      \"Enhanced Introspection\",\n+      \"Conceptual Thinking\",\n+      \"Unity and Interconnectedness\",\n+      \"Nausea (especially during come-up)\",\n+      \"Sedation and Body Heaviness\",\n+      \"Confusion\",\n+      \"Anxiety or Feelings of Impending Doom (typically during onset)\",\n+      \"Synaesthesia\",\n+      \"Tactile Enhancement\",\n+      \"Excessive Yawning\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"2 weeks\",\n+      \"full_tolerance\": \"After 1-2 consecutive days of use\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7-14 days\",\n-        \"Other tryptamine psychedelics (e.g., LSD, DMT)\"\n+        \"All psychedelics (LSD, mescaline, 2C-x, tryptamines)\"\n-    \"half_life\": \"1.5 - 3 hours (psilocybin); effects last longer due to active metabolite psilocin\",\n+    \"half_life\": \"1-3 hours (psilocin active metabolite)\",\n-        \"name\": \"Bluelight - Penis Envy Mushrooms Discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/penis-envy-mushrooms.520747/post-11662949\"\n+        \"name\": \"Erowid Psilocybin Mushroom Dosage\",\n+        \"reference\": \"https://erowid.org/plants/mushrooms/mushrooms_dose.shtml\"\n-        \"name\": \"Bluelight - Getting the Most Out of Mushrooms\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/getting-the-most-out-of-mushrooms.555352/page-2\"\n+        \"name\": \"PsychonautWiki: Psilocybin Mushrooms\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushrooms\"\n-        \"name\": \"Tripsitter Substack: Penis Envy Mushrooms\",\n-        \"reference\": \"https://tripsitter.substack.com/p/penis-envy-mushrooms?r=1da21z\"\n+        \"name\": \"TripSit Mushrooms Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/Mushrooms\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Psilocybin Mushrooms Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-psilocybin-mushrooms-thread.58587/\"\n+      },\n+      {\n+        \"name\": \"Drug Science: Psilocybin\",\n+        \"reference\": \"https://www.drugscience.org.uk/psilocybin\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Psychiatry: Therapeutic use of psilocybin\",\n+        \"reference\": \"https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1040217/full\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Psilocybin Mushroom Lemon Tek\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushroom_lemon_tek\"\n-      \"common\"\n+      \"classic-psychedelic\",\n+      \"tryptamine\",\n+      \"plant-based\"\n-  \"index-category\": \"\"\n+  \"index-category\": \"psychedelic;classic;tryptamine\"\n\n# Psilocin · #645\n\n+{\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+      ]\n+    },\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n+      \"Time Distortion\",\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+      },\n+      {\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"serotonergic\",\n+      \"entheogen\"\n+    ]\n+  },\n+  \"id\": 645\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-002145-da9fd05b",
    "createdAt": "2025-10-17T00:21:45.181Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:21:43 PM"
    },
    "articles": [
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      }
    ],
    "markdown": "# Psilocin · #645\n\n+{\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+      ]\n+    },\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n+      \"Time Distortion\",\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+      },\n+      {\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"serotonergic\",\n+      \"entheogen\"\n+    ]\n+  },\n+  \"id\": 645\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-001831-4cf48d4f",
    "createdAt": "2025-10-17T00:18:31.587Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:18:29 PM"
    },
    "articles": [
      {
        "id": 644,
        "title": "5-MeO-DiPT",
        "slug": "5-meo-dipt"
      }
    ],
    "markdown": "# 5-MeO-DiPT · #644\n\n+{\n+  \"title\": \"5-MeO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"5-MeO-DiPT\",\n+    \"chemical_name\": \"5-Methoxy-N,N-diisopropyltryptamine\",\n+    \"alternative_name\": \"Foxy; Foxy Methoxy\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic; Entactogen; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (primary); 5-HT1A receptor agonist (strongest binding affinity); weak serotonin reuptake inhibitor; possible monoamine oxidase inhibition\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3-4 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-15 mg\",\n+            \"strong\": \"15-20 mg\",\n+            \"heavy\": \"20+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2-4 mg\",\n+            \"light\": \"4-7 mg\",\n+            \"common\": \"7-12 mg\",\n+            \"strong\": \"12-18 mg\",\n+            \"heavy\": \"18+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2-3 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-8 mg\",\n+            \"strong\": \"8-12 mg\",\n+            \"heavy\": \"12+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"2-6 hours (residual stimulation, possible insomnia)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"1-3 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-6 hours (prolonged compared to other smoked tryptamines)\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"5-MeO-DiPT is not considered physically addictive and has low potential for psychological dependence. Some users report compulsive redosing due to the extended onset, particularly among inexperienced users who mistake the delayed effects for inadequate dosing. Tryptamines of this class are not known for addictive patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of serotonin syndrome; 5-MeO-DiPT may have weak MAOI properties)\",\n+        \"Tramadol (increased risk of serotonin syndrome and seizures)\",\n+        \"aMT (increased risk of serotonin syndrome)\"\n+      ],\n+      \"unsafe\": [\n+        \"2C-T-X (both classes unpredictable alone)\",\n+        \"2C-X (unpredictable potentiation of psychedelic effects)\",\n+        \"NBOMe (both classes unpredictable; increased risk of unpleasant physical side effects)\",\n+        \"DOx (unpredictable interactions; increased risk of unpleasant physical side effects)\",\n+        \"MDMA (5-MeO tryptamines unpredictable with MDMA)\",\n+        \"Mescaline (unpredictable interactions)\",\n+        \"DXM (little information; possible unpredictable effects)\",\n+        \"PCP (little information; may increase risk of psychosis and excessive stimulation)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (may increase risk of anxiety, paranoia, and psychosis)\",\n+        \"Amphetamines (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\",\n+        \"Cocaine (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\"\n+      ]\n+    },\n+    \"notes\": \"5-MeO-DiPT varies widely in individual response; some users report profound experiences while others experience uncomfortable gastrointestinal distress including severe diarrhea, gas, and stomach bloating. Use a precise milligram scale as dosages are in the low milligram range. The extended onset of 20-60 minutes has led to accidental overdoses from premature redosing. Individuals with personal or family history of psychotic disorders should avoid use. At least one death has been attributed to rectal administration overdose. The substance has been reported to be neurotoxic in rats. Set and setting are important; some users report significant anxiety and paranoia at higher doses.\",\n+    \"subjective_effects\": [\n+      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Emotional Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Libido\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Auditory Distortions\",\n+      \"Cognitive Euphoria\",\n+      \"Nausea\",\n+      \"Body Load\",\n+      \"Diarrhea\",\n+      \"Time Distortion\",\n+      \"Visual Drifting (at higher doses)\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"3-6 hours (estimated from duration data)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 5-MeO-DiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/5meo_dipt/\"\n+      },\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #37: 5-MeO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal37.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 5-MeO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/5-MeO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 5-MeO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-5-meo-dipt-thread.57817/\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combinations Wiki\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Shulgin, A. T.; Carter, M. F. (1980). Communications in Psychopharmacology\",\n+        \"reference\": \"N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity\"\n+      },\n+      {\n+        \"name\": \"Noworyta-Sokolowska et al. (2016). Neurotoxicity Research\",\n+        \"reference\": \"Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats\"\n+      },\n+      {\n+        \"name\": \"US DEA Drug Fact Sheet: 5-MeO-DiPT\",\n+        \"reference\": \"https://www.deadiversion.usdoj.gov/drug_chem_info/5meodipt.pdf\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"entactogen\"\n+    ]\n+  },\n+  \"id\": 644\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-001600-2209a8ec",
    "createdAt": "2025-10-17T00:16:00.464Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:15:58 PM"
    },
    "articles": [
      {
        "id": 643,
        "title": "4-HO-MPT",
        "slug": "4-ho-mpt"
      }
    ],
    "markdown": "# 4-HO-MPT · #643\n\n+{\n+  \"title\": \"4-HO-MPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-MPT\",\n+    \"chemical_name\": \"3-[2-(Methylpropylamino)ethyl]-4-indolol\",\n+    \"alternative_name\": \"Meprocin; 4-Hydroxy-N-methyl-N-propyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2B receptor partial agonist (moderate-efficacy); 5-HT2C receptor partial agonist (high-efficacy)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-7 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"45-90 minutes\",\n+            \"onset\": \"1-3 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"15-45 minutes\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-MPT is generally considered not habit-forming, and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is thought to be self-regulating with low potential for psychological dependence.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-MPT is a research chemical with very little history of human usage and minimal scientific data on its pharmacology, metabolism, and toxicity. Legal status varies by jurisdiction; it is unscheduled in most countries but is a Class A drug in the United Kingdom under the tryptamine catch-all clause and controlled under Germany's NpSG. Use precise scales for dosing as potency varies between salt forms (freebase is approximately 25% more potent than fumarate salts). Individuals with personal or family histories of mental illness should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Distortions And Patterning\",\n+      \"Color Enhancement And Shifting\",\n+      \"Time Distortion\",\n+      \"Emotion Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n+      \"Pupil Dilation\",\n+      \"Thought Loops\",\n+      \"Vertigo Or Dizziness\",\n+      \"Memory Suppression\",\n+      \"Internal And External Hallucinations\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (including LSD, psilocybin, mescaline, and other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-HO-MPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_mpt/4_ho_mpt.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki 4-HO-MPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-MPT\"\n+      },\n+      {\n+        \"name\": \"TripSit 4-HO-MPT Factsheet\",\n+        \"reference\": \"https://tripbot.tripsit.me/factsheet/4-HO-MPT\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #23: 4-HO-MPT (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=23\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-MPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-mpt-thread.550416/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum 4-HO-MPT Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/4-HO-MPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 643\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-001249-69555e3a",
    "createdAt": "2025-10-17T00:12:49.407Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:12:46 PM"
    },
    "articles": [
      {
        "id": 642,
        "title": "4-HO-EPT",
        "slug": "4-ho-ept"
      }
    ],
    "markdown": "# 4-HO-EPT · #642\n\n+{\n+  \"title\": \"4-HO-EPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-EPT\",\n+    \"chemical_name\": \"4-Hydroxy-N-ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Eprocin\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-20 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-7 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"15-30 minutes\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-EPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is generally considered self-regulating. There is no evidence of physical dependence potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-EPT is a novel research chemical with very little history of human use before 2016 and almost no scientific research on its pharmacology, metabolism, or toxicity. Unlike more visual tryptamines, it primarily enhances colors with a neon quality rather than producing strong visual distortions. Users report a strong euphoric body high sometimes compared to opiates, with a generally light and positive mindset. Accurate weighing with a precise milligram scale is essential. Individuals with personal or family history of psychotic disorders should avoid use. Higher doses may cause vasoconstriction. Set and setting considerations apply as with all psychedelics.\",\n+    \"subjective_effects\": [\n+      \"Color Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Euphoric Body High\",\n+      \"Increased Music Appreciation\",\n+      \"Conceptual Thinking\",\n+      \"Analysis Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Time Distortion\",\n+      \"Emotion Enhancement\",\n+      \"Sedation\",\n+      \"Memory Suppression\",\n+      \"Thought Loops\",\n+      \"Nausea\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-ept-thread.805165/\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-EPT Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_4HOEPT.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-HO-EPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?id=5770\"\n+      },\n+      {\n+        \"name\": \"PMC: Investigation of the Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-EPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 642\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000922-9ad8186d",
    "createdAt": "2025-10-17T00:09:22.650Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:09:20 PM"
    },
    "articles": [
      {
        "id": 641,
        "title": "4-HO-DiPT",
        "slug": "4-ho-dipt"
      }
    ],
    "markdown": "# 4-HO-DiPT · #641\n\n+{\n+  \"title\": \"4-HO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-ol\",\n+    \"alternative_name\": \"Iprocin; 4-Hydroxy-DiPT; 4-Hydroxy-N,N-diisopropyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; Serotonin reuptake inhibitor (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"60-90 minutes (20-30 minutes after onset)\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-DiPT is not habit-forming and has minimal psychological dependence potential. Like most psychedelics, it is considered self-regulating, with the desire to use it typically decreasing with regular consumption.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-DiPT is a research chemical with very limited history of human use and no scientific studies on its toxicity. It is noted for its uniquely rapid onset, short duration, narrow dose sensitivity, and high intensity relative to dose. Physical side effects including muscle tremors, leg tremors, bodily malaise, and temperature dysregulation are commonly reported. Set and setting are critical, and harm reduction practices are essential. The substance is unscheduled in most jurisdictions but may be controlled under analogue laws.\",\n+    \"subjective_effects\": [\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Introspective Insights\",\n+      \"Time Distortion\",\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Sexual Enhancement\",\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Muscle Tremors\",\n+      \"Nausea\",\n+      \"Pupil Dilation\",\n+      \"Stimulation\",\n+      \"Temperature Dysregulation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x, DOx, 5-MeO-xxT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"2.7-4.1 hours (based on prodrug luvesilocin studies)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_dipt/4_ho_dipt.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT by Alexander Shulgin\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=17\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-4-ho-dipt-thread.107890/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: 4-HO-DiPT Trip Reports\",\n+        \"reference\": \"https://drugs-forum.com/threads/4-ho-dipt-trip-reports.3095/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4-HO-DiPT\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Repke, D. B. et al. (1977). Psilocin analogs synthesis\",\n+        \"reference\": \"Journal of Heterocyclic Chemistry, 14(1), 71-74\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 641\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000655-9eafe3b2",
    "createdAt": "2025-10-17T00:06:55.306Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:06:53 PM"
    },
    "articles": [
      {
        "id": 640,
        "title": "4-HO-DET",
        "slug": "4-ho-det"
      }
    ],
    "markdown": "# 4-HO-DET · #640\n\n+{\n+  \"title\": \"4-HO-DET\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-DET\",\n+    \"chemical_name\": \"3-(2-diethylaminoethyl)-1H-indol-4-ol\",\n+    \"alternative_name\": \"Ethocin; CZ-74; 4-Hydroxy-N,N-diethyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"20-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2.5-3.5 hours (with 30-60 minute come up)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"1-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-DET is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. Limited evidence suggests no significant addiction potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, may significantly increase risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-DET is a research chemical with very little history of human usage. The toxicity and long-term health effects have not been studied in any scientific context. It is strongly recommended to use harm reduction practices when using this substance. Legal status varies by jurisdiction; it is unscheduled in the United States but may be prosecuted under the Federal Analogue Act. It is controlled in Germany, Sweden, Switzerland, and the United Kingdom.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Colour Enhancement\",\n+      \"Tactile Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Analysis Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Ego Death\",\n+      \"Memory Suppression\",\n+      \"Excessive Yawning\",\n+      \"Temperature Regulation Suppression\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight 4-HO-DET Discussion Thread\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/480200-The-Big-amp-Dandy-4-HO-DET-Thread\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-DET Experience Vaults\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_4HODET.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design TiHKAL Entry #16: 4-HO-DET\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5016\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DET\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4-HO-DET\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DET\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 640\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000420-1266ad24",
    "createdAt": "2025-10-17T00:04:20.477Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:04:18 PM"
    },
    "articles": [
      {
        "id": 639,
        "title": "4-AcO-MiPT",
        "slug": "4-aco-mipt"
      }
    ],
    "markdown": "# 4-AcO-MiPT · #639\n\n+{\n+  \"title\": \"4-AcO-MiPT\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-AcO-MiPT\",\n+    \"chemical_name\": \"4-Acetoxy-N-methyl-N-isopropyltryptamine\",\n+    \"alternative_name\": \"Mipracetin; O-Acetylmiprocin; 4-Acetoxy-MiPT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (prodrug of 4-HO-MiPT)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-20 mg\",\n+            \"strong\": \"20-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1.5-3 hours (come up 1-2 hours)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-AcO-MiPT is not habit-forming and demonstrates a self-regulating pattern typical of psychedelics. The desire to use it tends to decrease with regular consumption rather than increase.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, may significantly intensify effects)\"\n+      ]\n+    },\n+    \"notes\": \"4-AcO-MiPT is a synthetic psychedelic tryptamine that remains relatively uncommon with limited history of human use. The substance is hygroscopic and degrades quickly when exposed to moisture or improper storage; it should be kept in an inert atmosphere in a freezer. The material can develop a sticky, goop-like consistency when exposed to air. Accurate weighing with a precise milligram scale is essential, as the substance is potent and can appear deceptively small. It is theorized to act as a prodrug for 4-HO-MiPT, though debate continues about whether it possesses innate activity. Set and setting are critical factors for the experience.\",\n+    \"subjective_effects\": [\n+      \"Visual Geometry (Organic, Intricate, Natural-Feeling)\",\n+      \"Colour Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Sedation With Mild Euphoria\",\n+      \"Pleasurable Body High (Warm, Tingling Sensations)\",\n+      \"Excessive Yawning\",\n+      \"Enhanced Music Appreciation\",\n+      \"Auditory Distortions (Downward Pitch Shift)\",\n+      \"Emotion Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Time Distortion\",\n+      \"Internal Hallucinations (Dark Environments)\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-MiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_mipt/4_acetoxy_mipt.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-AcO-MIPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=5546\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-AcO-MiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-MiPT\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy 4-AcO-MiPT Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-aco-mipt-thread.101872/\"\n+      },\n+      {\n+        \"name\": \"Takahashi et al. - Psychoactive Designer Drugs Data Library\",\n+        \"reference\": \"https://doi.org/10.1016/j.talanta.2008.07.062\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 639\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-235801-dbfacf25",
    "createdAt": "2025-10-16T23:58:01.469Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:57:59 PM"
    },
    "articles": [
      {
        "id": 638,
        "title": "4-AcO-DiPT",
        "slug": "4-aco-dipt"
      }
    ],
    "markdown": "# 4-AcO-DiPT · #638\n\n+{\n+  \"title\": \"4-AcO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-AcO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate\",\n+    \"alternative_name\": \"4-Acetoxy-DiPT; Ipracetin; Iprocetyl; Aces; 4-Ace\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3-5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-4 hours\",\n+            \"onset\": \"15-40 minutes\",\n+            \"peak\": \"1.5-2 hours\",\n+            \"offset\": \"1-1.5 hours\",\n+            \"after_effects\": \"2-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-AcO-DiPT is not known to be habit-forming and the desire to use it can decrease with repeated administration. However, it may possess a higher liability for frequent or excessive consumption relative to most psychedelics due to its distinctly hedonic and short-duration effects. Compulsive redosing is reported to be atypically prominent for this substance.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"MAOIs (risk of serotonin syndrome)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (may significantly intensify and prolong effects unpredictably)\",\n+        \"Alcohol (physically taxing, may dull effects)\",\n+        \"Benzodiazepines (may reduce trip intensity)\"\n+      ]\n+    },\n+    \"notes\": \"4-AcO-DiPT is thought to act as a prodrug to 4-HO-DiPT (Iprocin). It is available in both freebase and HCl salt forms, with the freebase being approximately 10% more potent by weight. This substance is characterized by atypically strong physical euphoria and sensuality with minimal visual effects, distinguishing it from most other 4-substituted tryptamines. Accurate weighing with a milligram scale is essential. Individuals with personal or family histories of seizure disorders or psychotic conditions should avoid use. The compound can produce notable increases in body temperature, particularly at peak effects. Set and setting significantly influence the experience.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Increased Libido\",\n+      \"Sedation Followed By Stimulation\",\n+      \"Disinhibition\",\n+      \"Enhanced Sociability\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Changes In Felt Bodily Form\",\n+      \"Music Appreciation Enhancement\",\n+      \"Empathy And Affection Enhancement\",\n+      \"Minimal Visual Effects\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (e.g., psilocybin, LSD, mescaline, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"2-4 hours (rapidly metabolized to 4-HO-DiPT)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Primer by Toad\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt_primer.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-AcO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Bluelight 4-AcO-DiPT Discussion Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/4-aco-dipt-new-experience-10-mg-dose-to-test-the-waters.493414/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-AcO-DiPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5369\"\n+      },\n+      {\n+        \"name\": \"Human Hepatocyte 4-AcO-DiPT Metabolite Profiling Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9413566/\"\n+      },\n+      {\n+        \"name\": \"Investigation of Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+      },\n+      {\n+        \"name\": \"Pharmacologic Activity of Substituted Tryptamines Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10029822/\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal17.shtml\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 638\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-235243-ca7cd977",
    "createdAt": "2025-10-16T23:52:43.680Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:52:42 PM"
    },
    "articles": [
      {
        "id": 637,
        "title": "EPT",
        "slug": "ept"
      }
    ],
    "markdown": "# EPT · #637\n\n+{\n+  \"title\": \"EPT\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"EPT\",\n+    \"chemical_name\": \"N-Ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Ethylpropyltryptamine; N-Ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-1-amine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-110 mg\",\n+            \"heavy\": \"110+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"75-100 mg\",\n+            \"common\": \"100-150 mg\",\n+            \"strong\": \"150-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-60 mg\",\n+            \"strong\": \"60-100 mg\",\n+            \"heavy\": \"100+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"1-3 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"EPT does not appear to produce dependence and has low abuse potential, similar to other unsubstituted tryptamines like DMT, DET, and MET. Rapid tolerance development discourages frequent use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"MAOIs (unknown interactions with increased potency)\",\n+        \"Stimulants (increased anxiety and physical strain)\"\n+      ],\n+      \"caution\": [\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"Cannabis (may intensify anxiety or confusion)\"\n+      ]\n+    },\n+    \"notes\": \"EPT is a novel research chemical with very limited documentation and extremely sparse user reports. The toxicity profile is unknown and no scientific studies exist on its safety in humans. Effects are described as milder and less immersive than structurally similar tryptamines like DMT and DPT. EPT is typically sold as the fumarate salt rather than the hydrochloride form. Start with very low doses due to individual sensitivity variations and the lack of established safety data. Use precise milligram scales and practice comprehensive harm reduction including set and setting protocols.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Color Enhancement\",\n+      \"Drifting And Morphing\",\n+      \"Dissociative Feeling\",\n+      \"Body Heaviness\",\n+      \"Time Distortion\",\n+      \"Memory Suppression\",\n+      \"Increased Libido\",\n+      \"Nausea\",\n+      \"Motor Control Loss\",\n+      \"Pupil Dilation\",\n+      \"Thought Acceleration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Small & Handy EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-ept-thread.856610/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: EPT Experiences\",\n+        \"reference\": \"https://drugs-forum.com/threads/ept-experiences.298861/\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: EPT\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_EPT.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: EPT\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5075\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/EPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 637\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-234801-e17fa4f6",
    "createdAt": "2025-10-16T23:48:01.414Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:47:59 PM"
    },
    "articles": [
      {
        "id": 636,
        "title": "DET",
        "slug": "det"
      }
    ],
    "markdown": "# DET · #636\n\n+{\n+  \"title\": \"DET\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"DET\",\n+    \"chemical_name\": \"N,N-diethyl-2-(1H-indol-3-yl)ethanamine\",\n+    \"alternative_name\": \"Diethyltryptamine; N,N-diethyltryptamine; T-9\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-70 mg\",\n+            \"strong\": \"70-100 mg\",\n+            \"heavy\": \"100+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"2-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"DET is not believed to be habit-forming and the desire to use it can actually decrease with repeated use. No formal studies have been conducted on its addiction potential, but anecdotal evidence suggests no negative dependency patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (seizure risk and amplified intensity)\",\n+        \"MAOIs (serotonin syndrome risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (may cause anxiety, paranoia, and thought loops)\"\n+      ]\n+    },\n+    \"notes\": \"DET is a Schedule I controlled substance internationally under the UN Convention on Psychotropic Substances and is illegal in most countries. Unlike DMT, DET is orally active due to increased resistance to monoamine oxidase breakdown from its ethyl groups. The substance has extremely limited history of human use and no formal toxicity studies exist. Users should employ precise dosing with a milligram scale and ensure proper set and setting. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Color Enhancement\",\n+      \"Drifting and Morphing\",\n+      \"Internal Hallucinations\",\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Pupil Dilation\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n+      \"Conceptual Thinking\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid DET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/det/det.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DET\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #3: DET (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5003\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #3: DET (Erowid)\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal03.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: 5-substituted tryptamines discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/5-substituted-tryptamines.340503/\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 636\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-233259-3b3ee166",
    "createdAt": "2025-10-16T23:32:59.430Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:32:57 PM"
    },
    "articles": [
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      }
    ],
    "markdown": "# PRO-LAD · #635\n\n+{\n+  \"title\": \"PRO-LAD\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"PRO-LAD\",\n+    \"chemical_name\": \"(8beta)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide\",\n+    \"alternative_name\": \"N-Propylnorlysergic acid N,N-diethylamide; 6-Propyl-6-nor-lysergic acid diethylamide; N-PropylnorLSD\",\n+    \"chemical_class\": \"Lysergamide\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20 ug\",\n+            \"light\": \"50-100 ug\",\n+            \"common\": \"100-200 ug\",\n+            \"strong\": \"200-350 ug\",\n+            \"heavy\": \"350+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"1-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"PRO-LAD is not considered habit-forming and possesses self-regulating properties typical of psychedelics. The desire to use it may actually decrease with repeated administration. No formal dependence studies have been conducted.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of seizures and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants including amphetamines, cocaine, methylphenidate (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, and psychosis)\",\n+        \"MDMA (unpredictable synergy with potential neurotoxicity)\",\n+        \"Benzodiazepines (can reduce or eliminate psychedelic effects)\",\n+        \"Dissociatives (greatly enhanced effects and confusion)\",\n+        \"Other psychedelics (unpredictable synergistic intensification)\"\n+      ]\n+    },\n+    \"notes\": \"PRO-LAD is a research chemical with very limited history of human use and minimal scientific documentation regarding its pharmacology, metabolism, and long-term toxicity. Unlike LSD, PRO-LAD has a propyl chain at R6 which may result in slower absorption and different onset characteristics. Users should employ rigorous harm reduction practices including reagent testing, accurate weighing with a microgram scale, and having a trusted sober trip sitter present. Individuals with personal or family history of psychotic disorders should avoid use. PRO-LAD was first synthesized by Hoffman and Nichols in 1984 and later described by Alexander Shulgin in TiHKAL.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Color Enhancement\",\n+      \"Introspection\",\n+      \"Time Distortion\",\n+      \"Ego Death\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Enhanced Sense Of Humor\",\n+      \"Thought Connectivity\",\n+      \"Physical Euphoria\",\n+      \"Emotional Amplification\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and other lysergamides\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #51: PRO-LAD\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal51.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: PRO-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PRO-LAD\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Hoffman AJ, Nichols DE (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Journal of Medicinal Chemistry 28(9):1252-1255\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+      },\n+      {\n+        \"name\": \"Shulgin A, Shulgin A (1997). TiHKAL: Tryptamines I Have Known And Loved\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 635\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-225756-89bd9e8d",
    "createdAt": "2025-10-16T22:57:56.453Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:57:54 PM"
    },
    "articles": [
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      }
    ],
    "markdown": "# LSM-775 · #634\n\n+{\n+  \"title\": \"LSM-775\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"LSM-775\",\n+    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n+    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT1A receptor full agonist; 5-HT2A receptor partial agonist; 5-HT2B receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"250 ug\",\n+            \"light\": \"500-750 ug\",\n+            \"common\": \"750-1250 ug\",\n+            \"strong\": \"1250-1500 ug\",\n+            \"heavy\": \"1500+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-10 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Variable (residual sedation possible)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"LSM-775 is not considered habit-forming and possesses an intrinsic self-regulating quality similar to other psychedelics. Limited evidence suggests no significant dependence potential, though the substance has very little history of human use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increases anxiety, paranoia, and thought loops)\",\n+        \"Cannabis (unpredictable synergy; greatly increases risk of anxiety and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"MDMA (unpredictable synergy; potentially neurotoxic)\",\n+        \"Alcohol (increases dehydration and physical discomfort)\",\n+        \"Other psychedelics (unpredictable intensification)\"\n+      ]\n+    },\n+    \"notes\": \"LSM-775 is a novel lysergamide with approximately one-tenth the potency of LSD and a shorter duration. It is characterized by prominent dream-like sedation and significant nausea that may substantially reduce the experience's pleasantness. Use a precise milligram scale as doses are relatively high. Mental health screening is advised before use, particularly for individuals with personal or family history of psychotic disorders. Set and setting remain important factors. Legal status varies by jurisdiction; controlled in Germany and Switzerland as of 2019.\",\n+    \"subjective_effects\": [\n+      \"Dream-Like Sedation\",\n+      \"Prominent Nausea\",\n+      \"Visual Patterning And Geometry\",\n+      \"Time Distortion (Particularly Pronounced)\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations (Tingling)\",\n+      \"Music Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Perception Of Bodily Heaviness\",\n+      \"Drifting (Melting, Breathing, Morphing)\",\n+      \"Internal Hallucinations\",\n+      \"Analysis Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: LSM-775\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSM-775\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: LSM-775\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_LSM775.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: LSM-775\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy LSM-775 Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-lsm-775-lysergic-acid-morpholide-thread.775765/\"\n+      },\n+      {\n+        \"name\": \"Gogerty & Dille (1957): Pharmacology of d-LSM\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13476356/\"\n+      },\n+      {\n+        \"name\": \"Shulgin: TiHKAL - LSD-25 Entry\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+      },\n+      {\n+        \"name\": \"Brandt et al. (2018): Return of the Lysergamides Part IV\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28585392/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"novel-psychoactive-substance\"\n+    ]\n+  },\n+  \"id\": 634\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-224845-2e3cf1ee",
    "createdAt": "2025-10-16T22:48:45.174Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:48:42 PM"
    },
    "articles": [
      {
        "id": 633,
        "title": "MET",
        "slug": "met"
      }
    ],
    "markdown": "# MET · #633\n\n+{\n+  \"title\": \"MET\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"MET\",\n+    \"chemical_name\": \"N-Ethyl-N-methyltryptamine\",\n+    \"alternative_name\": \"Methylethyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; serotonin releasing agent (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked/vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-60 mg\",\n+            \"strong\": \"60-90 mg\",\n+            \"heavy\": \"90+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"60-70 mg\",\n+            \"light\": \"70-80 mg\",\n+            \"common\": \"80-110 mg\",\n+            \"strong\": \"110-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-50 mg\",\n+            \"strong\": \"50-70 mg\",\n+            \"heavy\": \"70+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked/vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"30-75 minutes\",\n+            \"onset\": \"30-60 seconds\",\n+            \"peak\": \"10-20 minutes\",\n+            \"offset\": \"20-40 minutes\",\n+            \"after_effects\": \"20-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"1.5-3 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"45-90 minutes\",\n+            \"after_effects\": \"30-120 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"MET is not considered habit-forming and appears to be self-regulating. Reports suggest the desire to use it may actually decrease with regular consumption, similar to other psychedelic tryptamines.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of serotonin syndrome and hypertensive crisis)\",\n+        \"Lithium (increased seizure risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety and cardiovascular strain)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may dampen or prolong effects)\",\n+        \"Cannabis (may intensify experience unpredictably)\"\n+      ]\n+    },\n+    \"notes\": \"MET is a research chemical with very limited human use history and unstudied toxicity profile. The freebase form can be harsh when insufflated or smoked. Use an accurate milligram scale for all routes of administration. Set and setting are crucial for psychedelic experiences. Unlike DMT, MET has oral activity without requiring an MAOI. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Geometry And Patterning\",\n+      \"Internal Hallucinations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Color Enhancement And Shifting\",\n+      \"Cognitive Euphoria\",\n+      \"Empathy And Sociability Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Time Distortion\",\n+      \"Confusion\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Minimal tolerance buildup with repeated use\",\n+      \"half_tolerance\": \"Unknown\",\n+      \"zero_tolerance\": \"Approximately 1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Other psychedelic tryptamines (minimal to none)\",\n+        \"Classic psychedelics (minimal to none)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy MET Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-met-thread.255405/\"\n+      },\n+      {\n+        \"name\": \"Erowid MET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/met/met.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: MET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MET\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Methylethyltryptamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Methylethyltryptamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 633\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-224503-b5466f8d",
    "createdAt": "2025-10-16T22:45:03.789Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:45:01 PM"
    },
    "articles": [
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      }
    ],
    "markdown": "# MiPLA · #632\n\n+{\n+  \"title\": \"MiPLA\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"MiPLA\",\n+    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 ug\",\n+            \"light\": \"100-150 ug\",\n+            \"common\": \"150-200 ug\",\n+            \"strong\": \"200-250 ug\",\n+            \"heavy\": \"300+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours (preceded by 45-90 minute come-up)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Minimal residual stimulation\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"MiPLA is not considered physically addictive and has low potential for psychological dependence, similar to other serotonergic psychedelics. Rapid tolerance development discourages frequent use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (amphetamine, cocaine, methylphenidate - increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"SSRIs (may alter or blunt effects)\"\n+      ]\n+    },\n+    \"notes\": \"MiPLA is a research chemical with very limited history of human use and minimal scientific study of its pharmacology, metabolism, and toxicity. It is approximately two to three times less potent than LSD and has a notably shorter duration of around 4-6 hours. The substance is generally described as producing less anxiety and a lighter headspace compared to LSD. Individuals with personal or family history of mental illness should avoid use. Use precise weighing equipment and employ harm reduction practices including careful set and setting preparation.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Geometric Patterns\",\n+      \"Cognitive Euphoria\",\n+      \"Analysis Enhancement\",\n+      \"Music Appreciation Enhancement\",\n+      \"Time Distortion\",\n+      \"Ego Death (at higher doses)\",\n+      \"Nausea\",\n+      \"Increased Body Temperature\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (due to 5-HT2A receptor activity)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (estimated based on duration profile)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: MiPLA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MiPLA\"\n+      },\n+      {\n+        \"name\": \"Erowid MiPLA Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_MIPLA.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy MIPLA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-mipla-methylisopropyllysergamide-thread.784440/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: MiPLA (PiHKAL)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5327\"\n+      },\n+      {\n+        \"name\": \"Halberstadt et al. (2018) - Pharmacological characterization of ECPLA\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s00213-018-5055-9\"\n+      },\n+      {\n+        \"name\": \"Nichols, D.E. (2001) - LSD and its lysergamide cousins\",\n+        \"reference\": \"The Heffter Review of Psychedelic Research, Vol. 2, pp. 80-87\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 632\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223851-15e5eaa2",
    "createdAt": "2025-10-16T22:38:51.510Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:38:49 PM"
    },
    "articles": [
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      }
    ],
    "markdown": "# LSA · #631\n\n+{\n+  \"title\": \"LSA\",\n+  \"index-category\": \"psychedelic; natural\",\n+  \"drug_info\": {\n+    \"drug_name\": \"LSA\",\n+    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n+    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (morning glory seeds)\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20-50 seeds\",\n+            \"light\": \"50-100 seeds\",\n+            \"common\": \"100-250 seeds\",\n+            \"strong\": \"250-400 seeds\",\n+            \"heavy\": \"400+ seeds\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-3 seeds\",\n+            \"light\": \"3-5 seeds\",\n+            \"common\": \"5-7 seeds\",\n+            \"strong\": \"7-12 seeds\",\n+            \"heavy\": \"12+ seeds\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (morning glory seeds)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"LSA is not considered to be addictive with low abuse potential. There is virtually no withdrawal syndrome when use is stopped, and animal studies have not demonstrated self-administration behavior predictive of abuse liability.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, and mania)\",\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may suppress visual and cognitive effects)\",\n+        \"MAOIs (may potentiate effects; use caution with potential for dangerous interactions with other substances)\",\n+        \"Dissociatives (greatly enhance cognitive, visual and hallucinatory effects with increased risk of confusion and psychosis)\",\n+        \"Alcohol (may reduce anxiety but can increase dehydration, nausea and physical fatigue)\",\n+        \"Benzodiazepines (can reduce trip intensity; useful for stopping bad trips but may cause amnesia)\",\n+        \"Other psychedelics (unpredictable synergy and intensification of effects)\"\n+      ]\n+    },\n+    \"notes\": \"LSA-containing seeds vary widely in alkaloid content between species, batches, and individual seeds. Commercial seeds are often treated with fungicides or pesticides that can be extremely toxic; only use organic, untreated seeds from trusted vendors. Heavy metal testing is recommended before consumption. Extraction methods can significantly reduce nausea and body load. Strong vasoconstriction is common and can cause painful leg cramping; avoid repeated use over short periods. Set and setting strongly influence the experience. Individuals with personal or family histories of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Sedation (setting-dependent)\",\n+      \"Physical Euphoria\",\n+      \"Visual Enhancements and Distortions\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Perception of Bodily Heaviness\",\n+      \"Motor Control Loss\",\n+      \"Nausea and Vasoconstriction\",\n+      \"Dream-Like State\",\n+      \"Introspection and Analysis Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Time Distortion\",\n+      \"Internal and External Hallucinations\",\n+      \"Thought Connectivity\",\n+      \"Music Appreciation Enhancement\",\n+      \"Spirituality Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin mushrooms, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (psilocin is referenced in the original document, but LSA half-life data is limited; serum concentrations detectable for 1-24 hours post-ingestion)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: LSA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: LSA\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Dosage\",\n+        \"reference\": \"https://erowid.org/chemicals/lsa/lsa_dose.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Effects\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy LSA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/lsas-subthread-extraction-of-lsas.123944/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: LSA Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Ergine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Ergine\"\n+      },\n+      {\n+        \"name\": \"Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review (MDPI, 2025)\",\n+        \"reference\": \"https://www.mdpi.com/2226-4787/13/4/98\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"natural\",\n+      \"ergoline\"\n+    ]\n+  },\n+  \"id\": 631\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223526-fd17483e",
    "createdAt": "2025-10-16T22:35:26.906Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:35:25 PM"
    },
    "articles": [
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      }
    ],
    "markdown": "# ETH-LAD · #630\n\n+{\n+  \"title\": \"ETH-LAD\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"ETH-LAD\",\n+    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"alternative_name\": \"N-Ethyl-nor-LSD; 6-Ethyl-6-nor-lysergic acid diethylamide; N-Ethyl-nor-lysergic acid N,N-diethylamide\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (high affinity); dopamine D1, D2, D3, D4, D5 receptor binding (lower affinity)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"30-60 ug\",\n+            \"common\": \"60-150 ug\",\n+            \"strong\": \"150-225 ug\",\n+            \"heavy\": \"225+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"4-6 hours (including 45-90 minute come up)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"8-48 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"ETH-LAD is not considered habit-forming and demonstrates a self-regulating quality typical of psychedelics. Rapid tolerance develops immediately after use, discouraging frequent consumption. Cases of abuse have been rarely reported, though the substance generally decreases in desirability with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Cannabis (unpredictable and strongly increased effects, risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants including amphetamine, cocaine, methylphenidate (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"ETH-LAD requires exceptional caution due to its high potency, unpredictable dose-response curve, and tendency to produce severe physical side effects including pronounced nausea, temperature dysregulation, muscle cramps, and bodily discomfort at higher doses. The substance is notably more difficult to handle than LSD and should only be used by experienced psychedelic users. Accurate measurement with a precise scale is critical. Users should monitor body temperature throughout the experience and maintain access to climate control. Set and setting are paramount, and having a trusted sober sitter is strongly recommended, especially at doses above the common range. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Intricate Visual Geometry\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Auditory Distortions and Hallucinations\",\n+      \"Analysis Enhancement\",\n+      \"Introspective Thought Patterns\",\n+      \"Time Distortion\",\n+      \"Synaesthesia\",\n+      \"Enhanced Color Perception\",\n+      \"Nausea and Bodily Discomfort\",\n+      \"Temperature Dysregulation\",\n+      \"Emotional Neutrality or Detachment\",\n+      \"Thought Acceleration\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and related lysergamides\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy ETH-LAD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-eth-lad-thread.761505/\"\n+      },\n+      {\n+        \"name\": \"Erowid ETH-LAD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_ETHLAD.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #12: ETH-LAD\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal12.shtml\"\n+      },\n+      {\n+        \"name\": \"Hoffman AJ, Nichols DE (1985) - Synthesis and LSD-like discriminative stimulus properties\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: TiHKAL ETH-LAD Entry\",\n+        \"reference\": \"http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=12\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: ETH-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ETH-LAD\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 630\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223152-65eead67",
    "createdAt": "2025-10-16T22:31:52.581Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:31:51 PM"
    },
    "articles": [
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      }
    ],
    "markdown": "# ALD-52 · #629\n\n+{\n+  \"title\": \"ALD-52\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"ALD-52\",\n+    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n+    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist; 5-HT1A receptor partial agonist; D2 receptor agonist (through LSD metabolite)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"30 ug\",\n+            \"light\": \"30-100 ug\",\n+            \"common\": \"100-175 ug\",\n+            \"strong\": \"175-325 ug\",\n+            \"heavy\": \"325+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"3-5 hours (following 1-2 hour come up)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"ALD-52 is not considered physically addictive and has extremely low potential for psychological dependence. The rapid development of tolerance discourages frequent use patterns, and the desire to use typically decreases with repeated exposure rather than increasing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"MAOIs (unpredictable effects, possible hypertensive reaction)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold, psychedelics may trigger seizures)\",\n+        \"Stimulants including amphetamines and cocaine (increased risk of anxiety, thought loops, cardiovascular strain)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictably strong synergy, increased risk of anxiety and paranoia)\",\n+        \"MDMA (may increase neurotoxicity, unpredictable synergy)\",\n+        \"Other psychedelics (intense cross-tolerance and potentially overwhelming effects)\",\n+        \"SSRIs (may blunt or alter effects)\"\n+      ]\n+    },\n+    \"notes\": \"ALD-52 functions as a prodrug for LSD, metabolizing into LSD in the body along with other metabolites. Legal status varies widely by jurisdiction; it is controlled in many countries including the UK, Germany, Switzerland, and Latvia, while remaining technically unscheduled in others such as the United States and Denmark. Individuals with personal or family history of psychotic disorders should avoid use. Famous for being mistakenly associated with 'Orange Sunshine' LSD from the 1960s, though this was later confirmed to be standard LSD at 300 micrograms per dose. Set and setting are critical for a positive experience, and users should approach this potent, long-lasting substance with proper preparation and harm reduction practices.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Sensory Perception\",\n+      \"Time Distortion\",\n+      \"Cognitive Euphoria\",\n+      \"Enhanced Introspection\",\n+      \"Emotional Amplification\",\n+      \"Physical Euphoria\",\n+      \"Thought Acceleration\",\n+      \"Enhanced Music Appreciation\",\n+      \"Pupil Dilation\",\n+      \"Increased Energy And Stimulation\",\n+      \"Novel Thought Patterns\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion, cross-tolerant with all psychedelics\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin mushrooms, mescaline, and tryptamines\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (LSD active metabolite)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid ALD-52 Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/lsd/lsd_ald52.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design TiHKAL Entry 26 (LSD)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/tk/26\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: ALD-52\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ALD-52\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy ALD-52 Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-ald-52-thread.773316/\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Wagmann et al. (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances\",\n+        \"reference\": \"https://doi.org/10.1007/s00216-018-1558-9\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"prodrug\"\n+    ]\n+  },\n+  \"id\": 629\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-222911-e7a3cfaa",
    "createdAt": "2025-10-16T22:29:11.119Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:29:09 PM"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n+{\n+  \"title\": \"1V-LSD\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"1V-LSD\",\n+    \"chemical_name\": \"1-Valeroyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (weak); acts as prodrug for LSD via deacylation\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"25-75 ug\",\n+            \"common\": \"75-150 ug\",\n+            \"strong\": \"150-300 ug\",\n+            \"heavy\": \"300+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"3-5 hours (come up 45-120 minutes)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"1V-LSD is assumed to be non-addictive with low abuse potential, similar to LSD. No literature reports exist of successful attempts to train animals to self-administer LSD analogs. There is virtually no withdrawal syndrome when chronic use is stopped.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Cannabis (strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\",\n+        \"MDMA (unpredictable synergy, potential increased neurotoxicity)\",\n+        \"Dissociatives (enhanced hallucinatory effects, increased risk of confusion and delusions)\",\n+        \"Benzodiazepines (reduce intensity of effects)\",\n+        \"Alcohol (may reduce anxiety but causes dehydration and physical discomfort)\"\n+      ]\n+    },\n+    \"notes\": \"1V-LSD is a novel research chemical with minimal history of human use and unverified safety profile. It is presumed to act as a prodrug for LSD. Those with personal or family history of mental illness should avoid use, particularly outside supervised medical settings. Set and setting are critical factors in determining experience quality. Start with lower doses due to individual variations in body weight, tolerance, metabolism, and sensitivity. No toxic dose is known, but higher doses increase risk of adverse psychological reactions. Test substances with reagent kits, though Ehrlich's reagent reacts slowly with N-acylated lysergamides.\",\n+    \"subjective_effects\": [\n+      \"Geometric Visual Hallucinations\",\n+      \"Time Distortion\",\n+      \"Enhanced Introspection\",\n+      \"Ego Loss\",\n+      \"Stimulation\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\",\n+      \"Emotion Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Creativity Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Unity And Interconnectedness\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Builds almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (including LSD, psilocybin, mescaline, DMT)\"\n+      ]\n+    },\n+    \"half_life\": \"Similar to LSD (estimated 3-5 hours for active metabolite)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: 1V-LSD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/1V-LSD\"\n+      },\n+      {\n+        \"name\": \"Erowid 1V-LSD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_1VLSD.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Small & Handy 1V-LSD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-small-handy-1v-lsd-thread.904997/\"\n+      },\n+      {\n+        \"name\": \"Brandt et al. (2022): Return of the lysergamides Part VII - Analytical and behavioural characterization of 1V-LSD\",\n+        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3205\"\n+      },\n+      {\n+        \"name\": \"Tripsitter: 1V-LSD - A New LSD Analog\",\n+        \"reference\": \"https://tripsitter.com/1v-lsd/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"prodrug\"\n+    ]\n+  },\n+  \"id\": 628\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-222618-76ba04c5",
    "createdAt": "2025-10-16T22:26:18.516Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:26:16 PM"
    },
    "articles": [
      {
        "id": 626,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      },
      {
        "id": 627,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      }
    ],
    "markdown": "# Diphenhydramine · #626\n\n+{\n+  \"title\": \"Diphenhydramine\",\n+  \"index-category\": \"deliriant; otc\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Diphenhydramine\",\n+    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n+    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n+    \"chemical_class\": \"Ethanolamine\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"100-200 mg\",\n+            \"common\": \"200-400 mg\",\n+            \"strong\": \"400-700 mg\",\n+            \"heavy\": \"700+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of severe anticholinergic effects)\",\n+        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"Tramadol (increased seizure risk)\",\n+        \"Alcohol (dangerous sedation, respiratory depression)\"\n+      ],\n+      \"caution\": [\n+        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n+        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n+        \"Opioids (increased sedation, respiratory depression)\"\n+      ]\n+    },\n+    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n+    \"subjective_effects\": [\n+      \"Sedation and Body Heaviness\",\n+      \"External Hallucinations (People, Objects, Insects)\",\n+      \"Auditory Hallucinations (Voices, Screams)\",\n+      \"Tactile Hallucinations (Phantom Sensations)\",\n+      \"Shadow People\",\n+      \"Delirium and Confusion\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Dysphoria and Anxiety\",\n+      \"Restless Leg Syndrome\",\n+      \"Dry Mouth and Dehydration\",\n+      \"Visual Acuity Suppression (Blurred Vision)\",\n+      \"Thought Disorganization\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n+      ]\n+    },\n+    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Diphenhydramine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Diphenhydramine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Diphenhydramine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Diphenhydramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n+      },\n+      {\n+        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n+      },\n+      {\n+        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"depressant\",\n+      \"antihistamine\",\n+      \"otc\"\n+    ]\n+  },\n+  \"id\": 626\n+}\n\n# Diphenhydramine · #627\n\n+{\n+  \"title\": \"Diphenhydramine\",\n+  \"index-category\": \"deliriant; otc\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Diphenhydramine\",\n+    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n+    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n+    \"chemical_class\": \"Ethanolamine\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"100-200 mg\",\n+            \"common\": \"200-400 mg\",\n+            \"strong\": \"400-700 mg\",\n+            \"heavy\": \"700+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of severe anticholinergic effects)\",\n+        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"Tramadol (increased seizure risk)\",\n+        \"Alcohol (dangerous sedation, respiratory depression)\"\n+      ],\n+      \"caution\": [\n+        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n+        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n+        \"Opioids (increased sedation, respiratory depression)\"\n+      ]\n+    },\n+    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n+    \"subjective_effects\": [\n+      \"Sedation and Body Heaviness\",\n+      \"External Hallucinations (People, Objects, Insects)\",\n+      \"Auditory Hallucinations (Voices, Screams)\",\n+      \"Tactile Hallucinations (Phantom Sensations)\",\n+      \"Shadow People\",\n+      \"Delirium and Confusion\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Dysphoria and Anxiety\",\n+      \"Restless Leg Syndrome\",\n+      \"Dry Mouth and Dehydration\",\n+      \"Visual Acuity Suppression (Blurred Vision)\",\n+      \"Thought Disorganization\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n+      ]\n+    },\n+    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Diphenhydramine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Diphenhydramine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Diphenhydramine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Diphenhydramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n+      },\n+      {\n+        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n+      },\n+      {\n+        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"depressant\",\n+      \"antihistamine\",\n+      \"otc\"\n+    ]\n+  },\n+  \"id\": 627\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-211713-87b4367c",
    "createdAt": "2025-10-16T21:17:13.242Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:17:09"
    },
    "articles": [
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      }
    ],
    "markdown": "# LSD · #191\n\n-    \"chemical_name\": \"LSD\",\n-    \"alternative_name\": \"Lysergic acid diethylamide\",\n+    \"chemical_name\": \"Lysergic acid diethylamide\",\n+    \"alternative_name\": \"Lucy; Acid\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"research-chemical\"\n+      \"common\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210951-3bc6b2e2",
    "createdAt": "2025-10-16T21:09:51.985Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:09:48"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 200,
        "title": "Psilocybin mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Psilocybin mushrooms · #200\n\n-  \"title\": \"Penis Envy\",\n+  \"title\": \"Psilocybin mushrooms\",\n-    \"drug_name\": \"Penis Envy\",\n-    \"chemical_name\": \"Penis Envy\",\n-    \"alternative_name\": \"Psilocybe cubensis, Penis Envy strain\",\n+    \"drug_name\": \"Psilocybin mushrooms\",\n+    \"chemical_name\": \"Psilocybin\",\n+    \"alternative_name\": \"Psilocybe cubensis; Magic mushrooms; Shrooms\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"research-chemical\"\n+      \"common\"\n\n# Amanita Muscaria · #201\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-120 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210536-524a89f5",
    "createdAt": "2025-10-16T21:05:36.034Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:05:33"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Amanita Muscaria · #201\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-120 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210425-092f4def",
    "createdAt": "2025-10-16T21:04:25.208Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:04:21"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210204-b30f4dee",
    "createdAt": "2025-10-16T21:02:04.651Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:02:01"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210000-f6e22140",
    "createdAt": "2025-10-16T21:00:00.495Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:59:57"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205923-297a11ac",
    "createdAt": "2025-10-16T20:59:23.332Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:59:20"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205842-8929e224",
    "createdAt": "2025-10-16T20:58:42.976Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:58:39"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205804-77914f41",
    "createdAt": "2025-10-16T20:58:04.237Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:58:00"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-204349-778df3a1",
    "createdAt": "2025-10-16T20:43:49.406Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:43:45"
    },
    "articles": [
      {
        "id": 59,
        "title": "Mescaline",
        "slug": "mescaline"
      },
      {
        "id": 60,
        "title": "5-MeO-DMT",
        "slug": "5-meo-dmt"
      },
      {
        "id": 73,
        "title": "4-HO-MET",
        "slug": "4-ho-met"
      },
      {
        "id": 79,
        "title": "EA-3167",
        "slug": "ea-3167"
      },
      {
        "id": 82,
        "title": "25I-NBOMe",
        "slug": "25i-nbome"
      },
      {
        "id": 102,
        "title": "4-AcO-DMT",
        "slug": "4-aco-dmt"
      },
      {
        "id": 106,
        "title": "Canket",
        "slug": "canket"
      },
      {
        "id": 107,
        "title": "FXE",
        "slug": "fxe"
      },
      {
        "id": 270,
        "title": "MAL",
        "slug": "mal"
      },
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      },
      {
        "id": 139,
        "title": "DOM",
        "slug": "dom"
      },
      {
        "id": 280,
        "title": "DOB",
        "slug": "dob"
      },
      {
        "id": 158,
        "title": "PMA",
        "slug": "pma"
      },
      {
        "id": 181,
        "title": "DiPT",
        "slug": "dipt"
      },
      {
        "id": 189,
        "title": "DXM Polistirex",
        "slug": "dxm-polistirex"
      },
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      },
      {
        "id": 196,
        "title": "Ibogaine",
        "slug": "ibogaine"
      },
      {
        "id": 199,
        "title": "Yopo",
        "slug": "yopo"
      },
      {
        "id": 200,
        "title": "Penis Envy",
        "slug": "penis-envy"
      },
      {
        "id": 205,
        "title": "Bromo-DragonFLY",
        "slug": "bromo-dragonfly"
      },
      {
        "id": 206,
        "title": "Kratom",
        "slug": "kratom"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 222,
        "title": "DOET",
        "slug": "doet"
      },
      {
        "id": 80,
        "title": "3-Quinuclidinyl benzilate",
        "slug": "3-quinuclidinyl-benzilate"
      },
      {
        "id": 346,
        "title": "Tilmetamine",
        "slug": "tilmetamine"
      },
      {
        "id": 239,
        "title": "2C-N",
        "slug": "2c-n"
      },
      {
        "id": 515,
        "title": "25T-2-NBOMe",
        "slug": "25t-2-nbome"
      },
      {
        "id": 263,
        "title": "DOC",
        "slug": "doc"
      },
      {
        "id": 266,
        "title": "TMA",
        "slug": "tma"
      },
      {
        "id": 264,
        "title": "2C-F",
        "slug": "2c-f"
      },
      {
        "id": 351,
        "title": "2-Chloroephenidine",
        "slug": "2-chloroephenidine"
      },
      {
        "id": 368,
        "title": "3,4-MD-PCP",
        "slug": "3-4-md-pcp"
      },
      {
        "id": 49,
        "title": "ALEPH",
        "slug": "aleph"
      },
      {
        "id": 268,
        "title": "ALEPH-2",
        "slug": "aleph-2"
      },
      {
        "id": 138,
        "title": "AMT",
        "slug": "amt"
      },
      {
        "id": 273,
        "title": "2C-P",
        "slug": "2c-p"
      },
      {
        "id": 276,
        "title": "3-HO-PCP",
        "slug": "3-ho-pcp"
      },
      {
        "id": 281,
        "title": "2C-EF",
        "slug": "2c-ef"
      },
      {
        "id": 285,
        "title": "DMT",
        "slug": "dmt"
      },
      {
        "id": 289,
        "title": "O-PCE",
        "slug": "o-pce"
      },
      {
        "id": 290,
        "title": "DMXE",
        "slug": "dmxe"
      },
      {
        "id": 257,
        "title": "DOEF",
        "slug": "doef"
      },
      {
        "id": 292,
        "title": "25CN-NBOH",
        "slug": "25cn-nboh"
      },
      {
        "id": 293,
        "title": "HXE",
        "slug": "hxe"
      },
      {
        "id": 295,
        "title": "2C-D",
        "slug": "2c-d"
      },
      {
        "id": 311,
        "title": "Cannabis",
        "slug": "cannabis"
      },
      {
        "id": 156,
        "title": "4-Methylthioamphetamine",
        "slug": "4-methylthioamphetamine"
      },
      {
        "id": 321,
        "title": "2C-C",
        "slug": "2c-c"
      },
      {
        "id": 326,
        "title": "DPT",
        "slug": "dpt"
      },
      {
        "id": 329,
        "title": "4-HO-PiPT",
        "slug": "4-ho-pipt"
      },
      {
        "id": 508,
        "title": "4-MeO-MiPT",
        "slug": "4-meo-mipt"
      },
      {
        "id": 338,
        "title": "4-HO-McPT",
        "slug": "4-ho-mcpt"
      },
      {
        "id": 392,
        "title": "2C-T-21",
        "slug": "2c-t-21"
      },
      {
        "id": 182,
        "title": "Sernyl",
        "slug": "sernyl"
      },
      {
        "id": 44,
        "title": "Dextromethorphan",
        "slug": "dextromethorphan"
      },
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      },
      {
        "id": 353,
        "title": "Ephenidine",
        "slug": "ephenidine"
      },
      {
        "id": 359,
        "title": "3-HO-PCE",
        "slug": "3-ho-pce"
      },
      {
        "id": 371,
        "title": "5-MeO-DPT",
        "slug": "5-meo-dpt"
      },
      {
        "id": 375,
        "title": "1B-LSD",
        "slug": "1b-lsd"
      },
      {
        "id": 401,
        "title": "2C-iP",
        "slug": "2c-ip"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      },
      {
        "id": 412,
        "title": "AL-LAD",
        "slug": "al-lad"
      },
      {
        "id": 425,
        "title": "5-MeO-DiBF",
        "slug": "5-meo-dibf"
      },
      {
        "id": 460,
        "title": "Scopolamine",
        "slug": "scopolamine"
      },
      {
        "id": 485,
        "title": "LSZ",
        "slug": "lsz"
      },
      {
        "id": 424,
        "title": "2-Me-DMT",
        "slug": "2-me-dmt"
      },
      {
        "id": 507,
        "title": "25P-NBOMe",
        "slug": "25p-nbome"
      },
      {
        "id": 518,
        "title": "2C-T-4-NBOMe",
        "slug": "2c-t-4-nbome"
      },
      {
        "id": 519,
        "title": "2C-T-7-NBOMe",
        "slug": "2c-t-7-nbome"
      },
      {
        "id": 531,
        "title": "25H-NBOMe",
        "slug": "25h-nbome"
      },
      {
        "id": 526,
        "title": "25I-NBMD",
        "slug": "25i-nbmd"
      },
      {
        "id": 528,
        "title": "25I-NBF",
        "slug": "25i-nbf"
      },
      {
        "id": 529,
        "title": "25I-NBOH",
        "slug": "25i-nboh"
      },
      {
        "id": 534,
        "title": "25C-NB3OMe",
        "slug": "25c-nb3ome"
      },
      {
        "id": 538,
        "title": "2-MeO-Ketamine",
        "slug": "2-meo-ketamine"
      },
      {
        "id": 539,
        "title": "2-MeO-DMT",
        "slug": "2-meo-dmt"
      },
      {
        "id": 540,
        "title": "2C-T-7",
        "slug": "2c-t-7"
      },
      {
        "id": 543,
        "title": "2C-B-FLY-NBOMe",
        "slug": "2c-b-fly-nbome"
      },
      {
        "id": 552,
        "title": "DCK",
        "slug": "dck"
      },
      {
        "id": 560,
        "title": "2-TFMXP",
        "slug": "2-tfmxp"
      },
      {
        "id": 570,
        "title": "4F-MDMB-BINACA",
        "slug": "4f-mdmb-binaca"
      },
      {
        "id": 583,
        "title": "AM-694",
        "slug": "am-694"
      },
      {
        "id": 584,
        "title": "ADBICA",
        "slug": "adbica"
      },
      {
        "id": 589,
        "title": "AMB-CHMICA",
        "slug": "amb-chmica"
      },
      {
        "id": 590,
        "title": "AMB-FUBINACA",
        "slug": "amb-fubinaca"
      },
      {
        "id": 594,
        "title": "CBNA",
        "slug": "cbna"
      },
      {
        "id": 597,
        "title": "Bufotenin",
        "slug": "bufotenin"
      },
      {
        "id": 599,
        "title": "Atropine",
        "slug": "atropine"
      },
      {
        "id": 600,
        "title": "AM-1248",
        "slug": "am-1248"
      },
      {
        "id": 605,
        "title": "25T-NBOMe",
        "slug": "25t-nbome"
      },
      {
        "id": 607,
        "title": "ADB-PINACA",
        "slug": "adb-pinaca"
      },
      {
        "id": 608,
        "title": "ADB-PINACA isomer 2",
        "slug": "adb-pinaca-isomer-2"
      },
      {
        "id": 609,
        "title": "AM-2201",
        "slug": "am-2201"
      },
      {
        "id": 611,
        "title": "BDCK",
        "slug": "bdck"
      },
      {
        "id": 616,
        "title": "AKB-57",
        "slug": "akb-57"
      },
      {
        "id": 622,
        "title": "4-MXP",
        "slug": "4-mxp"
      }
    ],
    "markdown": "# Mescaline · #59\n\n-      \"a-typical hallucinogen\",\n\n# 5-MeO-DMT · #60\n\n-      \"a-typical hallucinogen\",\n\n# 4-HO-MET · #73\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# EA-3167 · #79\n\n-      \"a-typical hallucinogen\",\n\n# 25I-NBOMe · #82\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-AcO-DMT · #102\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Canket · #106\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# FXE · #107\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# MAL · #270\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-BZ · #514\n\n-      \"a-typical hallucinogen\",\n\n# DOM · #139\n\n-      \"a-typical hallucinogen\",\n\n# DOB · #280\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# PMA · #158\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DiPT · #181\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DXM Polistirex · #189\n\n-      \"a-typical hallucinogen\",\n\n# LSD · #191\n\n-      \"a-typical hallucinogen\",\n\n# Ibogaine · #196\n\n-      \"a-typical hallucinogen\",\n\n# Yopo · #199\n\n-      \"a-typical hallucinogen\",\n\n# Penis Envy · #200\n\n-      \"a-typical hallucinogen\",\n\n# Bromo-DragonFLY · #205\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Kratom · #206\n\n-      \"a-typical hallucinogen\",\n\n# Amanita Muscaria · #201\n\n-      \"a-typical hallucinogen\",\n\n# Ibotenic acid · #215\n\n-      \"gabaergic\",\n-      \"A-typical hallucinogen\"\n+      \"gabaergic\"\n\n# DOET · #222\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 3-Quinuclidinyl benzilate · #80\n\n-      \"a-typical hallucinogen\",\n\n# Tilmetamine · #346\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-N · #239\n\n-      \"a-typical hallucinogen\",\n\n# 25T-2-NBOMe · #515\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DOC · #263\n\n-      \"stimulant\",\n-      \"a-typical hallucinogen\"\n+      \"stimulant\"\n\n# TMA · #266\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-F · #264\n\n-      \"a-typical hallucinogen\",\n\n# 2-Chloroephenidine · #351\n\n-      \"a-typical hallucinogen\",\n\n# 3,4-MD-PCP · #368\n\n-      \"a-typical hallucinogen\",\n\n# ALEPH · #49\n\n-      \"stimulant\",\n-      \"a-typical hallucinogen\"\n+      \"stimulant\"\n\n# ALEPH-2 · #268\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# AMT · #138\n\n-      \"a-typical hallucinogen\",\n\n# 2C-P · #273\n\n-      \"a-typical hallucinogen\",\n\n# 3-HO-PCP · #276\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-EF · #281\n\n-      \"a-typical hallucinogen\",\n\n# DMT · #285\n\n-      \"a-typical hallucinogen\",\n\n# O-PCE · #289\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# DMXE · #290\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DOEF · #257\n\n-      \"a-typical hallucinogen\",\n\n# 25CN-NBOH · #292\n\n-      \"a-typical hallucinogen\",\n\n# HXE · #293\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-D · #295\n\n-      \"a-typical hallucinogen\",\n\n# Cannabis · #311\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# 4-Methylthioamphetamine · #156\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-C · #321\n\n-      \"a-typical hallucinogen\",\n\n# DPT · #326\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-HO-PiPT · #329\n\n-      \"a-typical hallucinogen\",\n\n# 4-MeO-MiPT · #508\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-HO-McPT · #338\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-21 · #392\n\n-      \"a-typical hallucinogen\",\n\n# Sernyl · #182\n\n-      \"a-typical hallucinogen\",\n\n# Dextromethorphan · #44\n\n-      \"a-typical hallucinogen\",\n\n# MDA · #62\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Ephenidine · #353\n\n-      \"a-typical hallucinogen\",\n\n# 3-HO-PCE · #359\n\n-      \"a-typical hallucinogen\",\n\n# 5-MeO-DPT · #371\n\n-      \"a-typical hallucinogen\",\n\n# 1B-LSD · #375\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-iP · #401\n\n-      \"a-typical hallucinogen\",\n\n# Salvia · #409\n\n-      \"A-typical hallucinogen\",\n\n# AL-LAD · #412\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 5-MeO-DiBF · #425\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Scopolamine · #460\n\n-      \"deliriant\",\n-      \"a-typical hallucinogen\"\n+      \"deliriant\"\n\n# LSZ · #485\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2-Me-DMT · #424\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25P-NBOMe · #507\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-4-NBOMe · #518\n\n-      \"a-typical hallucinogen\",\n\n# 2C-T-7-NBOMe · #519\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25H-NBOMe · #531\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBMD · #526\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBF · #528\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBOH · #529\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25C-NB3OMe · #534\n\n-      \"a-typical hallucinogen\",\n\n# 2-MeO-Ketamine · #538\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2-MeO-DMT · #539\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-7 · #540\n\n-      \"a-typical hallucinogen\",\n\n# 2C-B-FLY-NBOMe · #543\n\n-      \"a-typical hallucinogen\",\n\n# DCK · #552\n\n-      \"a-typical hallucinogen\",\n\n# 2-TFMXP · #560\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4F-MDMB-BINACA · #570\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# AM-694 · #583\n\n-      \"a-typical hallucinogen\",\n\n# ADBICA · #584\n\n-      \"depressant\",\n-      \"a-typical hallucinogen\"\n+      \"depressant\"\n\n# AMB-CHMICA · #589\n\n-      \"a-typical hallucinogen\",\n\n# AMB-FUBINACA · #590\n\n-      \"a-typical hallucinogen\",\n\n# CBNA · #594\n\n-      \"nootropic\",\n-      \"a-typical hallucinogen\"\n+      \"nootropic\"\n\n# Bufotenin · #597\n\n-      \"a-typical hallucinogen\",\n\n# Atropine · #599\n\n-      \"deliriant\",\n-      \"a-typical hallucinogen\"\n+      \"deliriant\"\n\n# AM-1248 · #600\n\n-      \"a-typical hallucinogen\",\n\n# 25T-NBOMe · #605\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# ADB-PINACA · #607\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# ADB-PINACA isomer 2 · #608\n\n-      \"a-typical hallucinogen\",\n\n# AM-2201 · #609\n\n-      \"a-typical hallucinogen\",\n\n# BDCK · #611\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# AKB-57 · #616\n\n-      \"a-typical hallucinogen\",\n\n# 4-MXP · #622\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-191133-9b6f5ac8",
    "createdAt": "2025-10-16T19:11:33.130Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:11:30"
    },
    "articles": [
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      },
      {
        "id": 321,
        "title": "2C-C",
        "slug": "2c-c"
      }
    ],
    "markdown": "# 2C-BZ · #514\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"a-typical hallucinogen\",\n\n# 2C-C · #321\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"a-typical hallucinogen\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-191042-5c6a6d64",
    "createdAt": "2025-10-16T19:10:42.055Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:10:39"
    },
    "articles": [
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      }
    ],
    "markdown": "# 2C-BZ · #514\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"a-typical hallucinogen\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-190938-8a5873a8",
    "createdAt": "2025-10-16T19:09:38.185Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:09:35"
    },
    "articles": [],
    "markdown": "No diff details were provided for this commit.",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-083502-09318c26",
    "createdAt": "2025-10-16T08:35:02.514Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 2:35:00 AM"
    },
    "articles": [
      {
        "id": 36,
        "title": "Trazodone",
        "slug": "trazodone"
      },
      {
        "id": 86,
        "title": "Tranylcypromine",
        "slug": "tranylcypromine"
      },
      {
        "id": 144,
        "title": "Phenelzine",
        "slug": "phenelzine"
      },
      {
        "id": 186,
        "title": "Vilazodone",
        "slug": "vilazodone"
      },
      {
        "id": 303,
        "title": "Ondansetron",
        "slug": "ondansetron"
      },
      {
        "id": 302,
        "title": "Moclobemide",
        "slug": "moclobemide"
      },
      {
        "id": 301,
        "title": "Quetiapine",
        "slug": "quetiapine"
      },
      {
        "id": 307,
        "title": "Tianeptine",
        "slug": "tianeptine"
      },
      {
        "id": 374,
        "title": "Lean",
        "slug": "lean"
      },
      {
        "id": 430,
        "title": "Olanzapine",
        "slug": "olanzapine"
      },
      {
        "id": 442,
        "title": "Clobenzorex",
        "slug": "clobenzorex"
      },
      {
        "id": 458,
        "title": "Chlorpheniramine",
        "slug": "chlorpheniramine"
      },
      {
        "id": 530,
        "title": "Ro5-4864",
        "slug": "ro5-4864"
      }
    ],
    "markdown": "# Trazodone · #36\n\n-    \"psychoactive_class\": \"Antidepressant (Serotonin Antagonist and Reuptake Inhibitor, SARI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Tranylcypromine · #86\n\n-    \"psychoactive_class\": \"Antidepressant (Monoamine Oxidase Inhibitor, MAOI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Phenelzine · #144\n\n-    \"psychoactive_class\": \"Antidepressant (Monoamine Oxidase Inhibitor, MAOI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Vilazodone · #186\n\n-    \"psychoactive_class\": \"Antidepressant (Selective Serotonin Reuptake Inhibitor and 5-HT1A receptor partial agonist)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Ondansetron · #303\n\n-    \"psychoactive_class\": \"Antiemetic (not psychoactive in the traditional sense, but acts on the central nervous system to prevent nausea/vomiting)\",\n+    \"psychoactive_class\": \"Antiemetic\",\n\n# Moclobemide · #302\n\n-    \"psychoactive_class\": \"Antidepressant (Reversible MAO-A inhibitor)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Quetiapine · #301\n\n-    \"psychoactive_class\": \"Atypical antipsychotic\",\n+    \"psychoactive_class\": \"Antipsychotic (atypical)\",\n\n# Tianeptine · #307\n\n-    \"psychoactive_class\": \"Full μ-opioid receptor agonist; atypical antidepressant\",\n+    \"psychoactive_class\": \"Full μ-opioid receptor agonist; Antidepressant (atypical)\",\n\n# Lean · #374\n\n-    \"psychoactive_class\": \"Opioid depressant; antihistamine sedative\",\n+    \"psychoactive_class\": \"Opioid depressant; Antihistamine; Sedative\",\n\n# Olanzapine · #430\n\n-    \"psychoactive_class\": \"Atypical antipsychotic (multi-receptor antagonist)\",\n+    \"psychoactive_class\": \"Antipsychotic (atypical)\",\n\n# Clobenzorex · #442\n\n-    \"psychoactive_class\": \"Catecholaminergic stimulant; prodrug that yields d-amphetamine (~15 % conversion)\",\n+    \"psychoactive_class\": \"Stimulant; prodrug that yields d-amphetamine (~15 % conversion)\",\n\n# Chlorpheniramine · #458\n\n-    \"psychoactive_class\": \"Antihistamine (H1 receptor antagonist)\",\n+    \"psychoactive_class\": \"Antihistamine\",\n\n# Ro5-4864 · #530\n\n-    \"psychoactive_class\": \"atypical benzodiazepine; TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",\n+    \"psychoactive_class\": \"Benzodiazepine (atypical); TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251014-233456-d6536e79",
    "createdAt": "2025-10-14T23:34:56.256Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/14/2025, 5:34:54 PM"
    },
    "articles": [
      {
        "id": 294,
        "title": "Bromantane",
        "slug": "bromantane"
      }
    ],
    "markdown": "### Bromantane · #294\n\n- `drug_info.psychoactive_class`: \"Stimulant actoprotector; anxiolytic nootropic\" → \"Stimulant actoprotector; anxiolytic; nootropic\"",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251014-233158-373c6f71",
    "createdAt": "2025-10-14T23:31:58.069Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/14/2025, 5:31:55 PM"
    },
    "articles": [
      {
        "id": 152,
        "title": "Dimenhydrinate",
        "slug": "dimenhydrinate"
      },
      {
        "id": 396,
        "title": "Propranolol",
        "slug": "propranolol"
      },
      {
        "id": 417,
        "title": "Avizafone",
        "slug": "avizafone"
      }
    ],
    "markdown": "### Dimenhydrinate · #152\n\n- `drug_info.psychoactive_class`: \"Deliriant (anticholinergic); Antihistamine; Anti-emetic\" → \"Deliriant; Antihistamine; Anti-emetic\"\n\n### Propranolol · #396\n\n- `drug_info.psychoactive_class`: updated long text (98 characters; starts \"Not typically classified as psychoactive; Antihypertensive; antiarrhy...\") → text (\"Not typically classified as psychoactive; Antihypertensive; antiarrhythmic; anxiolytic\")\n\n### Avizafone · #417\n\n- `drug_info.psychoactive_class`: \"Sedative-hypnotic; anxiolytic (benzodiazepine)\" → \"Sedative-hypnotic; anxiolytic\"",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251013-212828-39bd2cd6",
    "createdAt": "2025-10-13T21:28:28.668Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 13/10/2025, 23:28:26"
    },
    "articles": [
      {
        "id": 595,
        "title": "1cP-MiPLA",
        "slug": "1cp-mipla"
      }
    ],
    "markdown": "### 1cP-MiPLA · #595\n\n- `drug_info.dosages.routes_of_administration[0].dose_ranges.heavy`: \"300 µg +\" → \"300 µg +\"\n- `drug_info.dosages.routes_of_administration[1].dose_ranges.heavy`: \"250 µg +\" → \"250 µg +\"\n- `drug_info.categories[1]`: \"a-typical hallucinogen\" → \"research-chemical\"\n- `drug_info.categories[2]`: removed text (\"research-chemical\")",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251013-212356-370466a5",
    "createdAt": "2025-10-13T21:23:56.596Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 13/10/2025, 23:23:53"
    },
    "articles": [],
    "markdown": "No changelog details were provided for this commit.",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251013-210154-43d82145",
    "createdAt": "2025-10-13T21:01:54.147Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/13/2025, 3:01:52 PM"
    },
    "articles": [
      {
        "id": 33,
        "title": "3-MeO-PCP",
        "slug": "3-meo-pcp"
      }
    ],
    "markdown": "### 3-MeO-PCP · #33\n\n- `drug_info.alternative_name`: added text (\"3-Methoxyphencyclidine\")",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251012-120815-ffa8a8d5",
    "createdAt": "2025-10-12T12:08:15.759Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/12/2025, 6:08:14 AM"
    },
    "articles": [
      {
        "id": 510,
        "title": "3-Cl-PCP",
        "slug": "3-cl-pcp"
      }
    ],
    "markdown": "### 3-Cl-PCP · #510\n\n- `drug_info.categories[2]`: removed (was `a-typical hallucinogen`)"
  },
  {
    "id": "20251012-120542-f6e605f4",
    "createdAt": "2025-10-12T12:05:42.088Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/12/2025, 6:05:40 AM"
    },
    "articles": [
      {
        "id": 389,
        "title": "3-MeO-PCMo",
        "slug": "3-meo-pcmo"
      }
    ],
    "markdown": "### 3-MeO-PCMo · #389\n\n- `content`: `# 3-MeO-PCMo\n## Arylcyclohexylamine (morpholine subgroup) | Dissociative NMDA-receptor antagonist with mild monoaminergic activity\n      \nPotency is roughly 1/10 of 3-MeO-PCP but still active in double-digit milligram range; weigh on 0.001 g scale and perform 1-3 mg allergy test. Virtually no clinical history: all human data are anecdotal. Reports of confusion, mania and prolonged delirium at heavy doses. Limited reagent-test data; use full panel to rule out NBOMe / opioid adulterants. Crystal often hygroscopic – store in airtight, light-protected container with desiccant.` → ``"
  }
]